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ABSTRACT

Charcot Marie Tooth disease (CMT) represents the most common inheritable peripheral
group of motor and sensory disorders; affecting 1 in 2500 people worldwide. Individuals
with CMT experience slow progressing weakness of the muscle, atrophy, mild loss of
motor coordination and in some cases loss of sensory function in the hands and feet
which could ultimately affect mobility. Dynein is an essential molecular motor that
functions to transport cargos in all cells. A point mutation in the dynein heavy chain was
discovered to cause CMT disease in humans, specifically CMT type 2O. We generated a
knock-in mouse model bearing the same mutation(H304R) in the dynein heavy chain to
study the disease. We utilized behavioral assays to determine whether our mutant mice
had a phenotype linked to CMT disease. The mutant mice had motor coordination defects
and reduced muscle strength compared to normal mice. To better understand the disease
pathway, we obtained homozygous mutants from a heterozygous cross, and the
homozygotes show even more severe deficits compared to heterozygotes. They also
developed an abnormal gait which separates them from heterozygous mice. In view of the
locomotor deficits observed in mutants, we examined the neuromuscular junction (NMJ)
for possible impairments. We identified defects in innervation at the later stages of the
study and abnormal NMJ architecture in the muscle as well. The dysmorphology of the
NMJ was again worse in the homozygous mutants with reduced complexity and
denervation at all the timepoints assessed. Our homozygous dynein mutants can live up to
two years and therefore make the design of longitudinal studies possible.
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Altogether, this mouse model provides dynein researchers an opportunity to work
towards establishing the link between dynein mutations, dynein dysfunction and the onset
and progression of disease.
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CHAPTER 1:INTRODUCTION
1.1

Cytoplasmic Dynein

Intracellular transport is at the heart of the maintenance of function and structure in the
eukaryotic cell. Cytoskeletal based molecular motors therefore play essential roles in the
cell since they transport various cargoes from one part of the cell to the other.
Cytoplasmic dynein is a 1.6 Mega Dalton motor protein that transports cargo retrogradely
on microtubule tracks. Dynein is important in mitosis and the transport of intracellular
cargoes such as mRNA-protein complexes, viruses and other organelles towards the
center of the cell (Bhabha et al, 2016).

Dynein belongs to the AAA+ (ATPases Associated with various cellular Activities)
family of proteins (Neuwald, 1999). This sets it apart from the other molecular motors
kinesin and myosin which are part of the G-protein family (Vale and Milligan, 2000).
Myosin functions in the muscle and moves on actin tracks, but dynein and kinesin move
along microtubules transporting cargo. There are over 15 kinesins which function as plus
and minus-ended motors, whereas cytoplasmic dynein is solely a minus-end directed
cargo. Dynein consists of 4 types of subunits namely the heavy chains, intermediate
chains, light intermediate chains and light chains (Figure1A). The heavy chain is the
largest subunit with a molecular weight of approximately 500kDa. There are two heavy
chains per molecule, and each contains the ATPase domains at the C-terminal end
responsible for mechanical force for movement.
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Figure 1 The Structure of Dynein and Dynactin
A) The 4 subunits of dynein as well as the functional sites required for normal activity in
cells B) The major activator of dynein, with its subunits and some of the functional
domains
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There are 6 AAA+ domains in the dynein heavy chain and AAA1 is believed to be where
most of the ATP hydrolysis occurs (Gibbons et al,1987). AAA3 and AA4 are also able to
cleave ATP and further experiments show that when nucleotide binding is interrupted in
these domains there is a corresponding change in dynein motility (Cho et al, 2008;
DeWittt et al, 2015; Silvanovich et al, 2003). AAA5 and AAA6 do not bind nucleotides
but help the motor detach from microtubules via a coupled rotational movement (Schmidt
et al, 2014). Cytoplasmic dynein binds microtubules with a 15nm coiled coil stalk
projecting from AAA4. The stalk has a specialized α-helical domain for microtubule
binding (Carter et al, 2008; Carter et al, 2011). The tail segment or N-terminal region of
the dynein heavy chain dimerizes and provides the sites for attachment of the other
dynein subunits namely the intermediate chain, light intermediate chain and light chains.
The intermediate chain is the site of attachment of important dynein regulators such as
Nudel/NudE, Lis1 and dynactin (McKenney et al, 2011; Nyarko et al, 2012). The light
chains are the sites of cargo attachment and are also the smallest of the dynein subunits.
Rp3 (13kD), Tctex-1 (12.4kD), LC8 (10.3kD) and LC7/robl (11kD) (King et al, 1998.
King et al,2002). siRNA depletion experiments involving some light chains points to a
role in endosome trafficking and mitosis (Palmer et al, 2009.)

Dynein is ubiquitously expressed in all cells and is critical during development. For
instance, during mitosis it generates the force that is required to organize the
microtubules and position the spindles. Dynein transports checkpoint proteins that play a
role in regulating mitosis (Howell et al, 2001 & Varma et al, 2008). Dynein function
requires dynactin, an adaptor found to make the motor protein processive (King and
3

Schroer,2000). Dynactin has a size of about 1MDa and is made up of 11 subunits with
the largest being p150 (Figure 1B). Dynactin interacts with dynein via its p150 subunit,
which bears a CAP-Gly (cytoskeleton-associated protein glycine-rich) domain to attach
to microtubules thereby ensuring that dynein does not fall off the microtubules. Dynactin
is needed in most of the dynein cellular functions; there is some evidence for the
attachment of cargos to both dynein and dynactin (Allan, 2011). The intermediate chain
of dynein and p150 of dynactin interact directly to ensure the proper microtubule
arrangement within cells and architecture of the centrosome (King et al, 2003). The Arp1
filament of dynactin associates with βIII spectrin, a surface protein on Golgi and some
membranes which might implicate a role in the movement of vesicles. Interactions have
also been reported with COPII vesicle protein SEC23 and a Rab7 GTPase effector, RILP
(Rab-interacting lysosomal protein) (Kardon & Vale, 2009).

Apart from dynactin, there are other accessory proteins that are necessary for proper
dynein function, these include LIS1, NudE/Nudel, BicD and ZW10. Mutations in LIS1
have been implicated in Lissencephaly or smooth brain; a neurological disorder affecting
development with the hallmark features of a smooth cerebrum, intellectual defects and
seizures. The disorder arises from impairments in proliferation of progenitor cells,
nucleokinesis and neuronal migration (Reiner, 2013). Lis1 is the only known dynein
regulator which is able to interact directly with the motor domain, specifically AAA3 and
AAA4, suggesting a more significant effect on dynein’s motion and function as well
(Huang et al, 2012. Toropova et al, 2014). More evidence of Lis1 involvement in
neurodevelopment is observed in its association with Nudel and NudE. These
4

homologous proteins are essential for mitosis and neurodevelopment. (Bradshaw et al,
2013). NudE recruits Lis1 to dynein and their added effect allows dynein to generate the
drag force to move heavy cargo like the nucleus. Nudel on the other hand may work
conversely by preventing the motor protein from attaching to microtubules (McKenney et
al, 2010). The Axon initial segment (AIS) is the location where nerve impulses are
initiated, it also serves as a neuronal barrier that helps differentiate dendritic identity from
axonal identity during neuronal development (Palay et al,1968; Rasband, 2010). The
maintenance of a peculiar identity by either the axon or dendrite is found to be dependent
partly on the activity of motor proteins. Nudel has been shown to associate with an
essential organizer of the AIS, Ankyrin G. A Lis1- mediated pathway leads to the
activation of dynein and transport of cargo out of the AIS (Kuijpers et al,2016).

ZW10 is a part of a complex that attaches to the kinetochore and binds it to microtubules.
ZW10 is responsible for targeting dynactin and dynein to the kinetochore (Stehman et al,
2007, Starr et al, 1998). Although it is directly bound to the p50 protein of dynactin,
ablation of ZW10 results in the loss of dynein at kinetochores, indicating that ZW10
perhaps indirectly stabilizes dynein at the kinetochores. BicD was discovered in
Drosophila as a factor that links dynein to some of its cargoes. Structural studies showed
that the CC1 and CC2 domains at the N-terminal of BicD bind to dynein and dynactin,
whereas the CC3 domain might specifically bind to cargoes such as Rab6 and some
pathogen-linked proteins (Liu et al, 2013). BicD like some other linker proteins are being
appreciated more and more as more than just cargo adapters but regulators of dynein
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motility. For instance, there are suggestions that BicD could influence the processivity of
dynein (Schlager et al, 2014).

1.2

Dynein Heavy Chain Mutations & Disease Models

Axonal transport is particularly vital to the functions of neurons given the distance that
separates the soma from the synaptic region at the tip of the axon and dendritic
compartments. Transport and timely delivery of cellular cargo to the right targets
prevents the disruption of neuronal functions that could possibly result in disease.

Our initial understanding of dynein structure and functions have come from experiments
in cell culture targeting dynein transport mechanisms and their effect on the so-called
housekeeping roles of dynein in the cell. Previous researchers showed that dynein null
mice die at the embryonic stage suggesting the need for dynein in development (Harada
et al, 1998). This broadly established dynein as an essential factor that supports life
making it even more worth studying. Other studies brought insights into more of the roles
of dynein, such as the trafficking of endosomes and lysosomes, organelles and mitosis
(Moore and Cooper, 2010). Genetic manipulations in yeast and fungi have been
invaluable in shedding more light on how dynein mutations might result in disease
(Sivagurunathan, S. et al. 2012, Qiu et al, 2013). Some of the mutations disrupt axonal
transport, which is a well-known mechanism in the occurrence of neurodegenerative
diseases like Parkinson’s, Alzheimer’s and Huntingtin’s (Liu et al, 2012; Lloyd, 2012;
Vicario Orri et al, 2015; Hoang et al,2017). Some of these mutations affect not only the
6

motor proteins themselves and but accessory proteins that aid them perform multiple
roles. Additionally, the cytoskeleton, which constitute the tracks on which the motors
travel, can also be targets of mutations that in turn hinder molecular motors and
eventually result in disease (Poirier et al,2013; Kumar et al, 2010). This makes the case
for the need to the understand all the complex interactions associated with molecular
motors as it is crucial to the pathology of neurodegenerative disease.

The heavy chain of cytoplasmic dynein, in particular, has been the protein of interest with
over 20 mutations recorded to date and known to cause various neurological disorders in
humans (Figure 2). The dynein heavy chain is a 532 kDa protein encoded by a single
gene, DYNC1H1 (Banks and Fisher, 2008). Interest in the heavy chain of dynein was
further heightened with the generation of animal models by ENU mutagenesis named
‘legs at odd angles’ or Loa , (Rogers et al, 2001 ) ‘cramping’ or Cra ( Hrabe de Angelis
et al,2000) and the ‘sprawling’ mutation or Swl produced by irradiation (Duchen, 1975).
There are some phenotypes that these early dynein mouse models have in common. The
mice showed abnormal hind limb posture when suspended by the tail as well as abnormal
gait and general muscle weakness. These mutations also disrupt dynein-driven retrograde
transport involving various cargoes in one way or the other. As much as there are
common features with the various mutations there are also unique the ways the function
of the protein is altered based on where the mutation is in the heavy chain. (Hafezparast
et al, 2003) reported the loss of motor neurons in both Loa and Cra heterozygote mice,
(Dupuis et al, 2009) on the other hand reported sensory neuron degeneration in Cra
heterozygous mice, (Chen et al, 2007) showed that Swl heterozygotes also lose
7

proprioceptive sensory neurons and muscle spindles. Experiments with homozygous mice
from all 3 genotypes revealed severe defects in development, which explains why they
are lethal at the embryonic stage. Loa homozygotes showed delayed migration of
neurons on the hippocampus and defects in the layers of the cortex (Ori-McKenney and
Vallee, 2011). Homozygotes with the Cra mutation were found to have defects in
morphology and arborization of dendrites culture from the striatum (Braunstein et al,
2010). Embryos from Swl homozygotes were found to be abnormal and had
developmental defects and died by E8.5. (Zhao et al, 2016).

Actual human mutations in the dynein heavy chain documented over the years are
characterized by developmental deficits and a dysfunction of parts of the neurological
system (Schiavo et al, 2013). The incidence of malformations of cortical development
(MCD) in 11 patients was traced to mutations in the dynein heavy chain (Poirier et
al,2013). Some of the mutations possibly affect specifically the motor and sensory
neurons and are characterized by weakness in the muscle and atrophy (Weedon et al,
2011). In some cases, progressive muscle degeneration is observed classically referred to
as spinal muscular atrophy with lower extremity predominance or SMA-LED (Harms et
al, 2012, Tsurusaki et al, 2012). Some human mutations in the dynein heavy chain were
found to cause severe intellectual disability (Willemsen et al, 2012). Another study
employing exome sequencing of the dynein heavy chain uncovered 8 de novo mutations
and 1 familial mutation from a screen of patients with various brain malformations such
as microcephaly and abnormalities on the cortex (Poirier et al, 2013).
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Figure 2 Schematic representation of mutations in the dynein heavy chain.
The diagram shows the different mutations that have been reported to date in the dynein
heavy chain (about 4644 amino acids). Human mutations are differentiated from the
mouse mutations, P1-P5 represent the ATPase domains, and C represents the C-terminal
end.
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The wide phenotypic spectrum which has clearly become the hallmark of dynein –related
disorders could be due to the multifarious roles of dynein inside the organism and in the
case of neurological disorders, the transport of different cargos that impact different
processes. These factors could determine the sensitivity of a group of neurons over the
other and therefore predict which neurological function will be compromised.

Different phenotypes are observed in human subjects with dynein heavy chain mutations,
however the question of how and why still remains. It is possible that it is a result of the
myriad of roles that dynein performs in cells. While there is no simple straightforward
answer, we can learn a lot of useful information by relating the structure of dynein to its
functions. It is important to investigate how mutations alter the dynein molecule and
whether or not it’s functions are altered as a result.

Evidence of the heterogeneity in phenotypes were initially observed in the animal
models. For example, sensory deficits were seen in Swl and Loa mice but not in mice
with the Cramping mutation. There was a reduction in the number of alpha motor
neurons in the spinal cord of Loa and Cra mice but no motor neuron loss was recorded in
Swl mice (Banks and Fisher, 2008). Heterogeneity in the dynein heavy chain mutations
was reiterated when 34 mutations were generated in Neurospora crassa (Sivagurunathan
et al, 2012,) The length-dependent theory of dynein heavy chain mutations based on
disrupted transport over long distances in axons would presume a bias towards the
peripheral nerves instead of nerves in the brain or spinal cord. Yet, there are patients with
deformities in the cerebral cortex and cognitive impairments all arising from mutations in
10

the dynein heavy chain. The effects of dynein heavy chain mutations on the CNS have
previously been observed alongside peripheral neuropathies. For instance, in CMT2O,
which predominantly manifests in muscle weakness and atrophy, at least 2 patients were
reported with severe intellectual disability as a result of dynein heavy chain mutations
(Weedon et al, 2011).

1.3

Importance of Axonal Transport

The distance that separates the soma from the synapse in neurons makes timely
communication between these compartments very crucial. This issue of distance is
accentuated by the fact that protein synthesis does not occur in some axons, hence the
need to ferry the needed proteins from the soma. (Morfini et al,2009). The unique
functions of dynein in neurons unlike the ‘so-called’ general housekeeping functions
have been studied extensively as a result of phenotypes observed from many heavy chain
mutations.

Defects in axonal transport have been highlighted in relation to neurodegenerative
diseases in amyotrophic lateral sclerosis (ALS) (LaMonte et al, 2002 & Strom et al,
2008), spinal muscular atrophy (SMA), (Puls et al, 2008), Huntingtin disease (Trushina
et al, 2004) and tauopahies (Ishihara et al, 1999, Ebneth et al, 1999). The cargos
involved and the extent to which they facilitate disease progression varies. The transport
of synucleins may play a role in the pathogenesis of Parkinson’s disease (Jenssen et al,
1999), presenilin-1 and the amyloid precursor protein transport are important in
11

Alzheimer’s (Papp et al, 2002), and problems related to the transport of mitochondria
accounts for some of the dynein associated mutations (Eschbach et al, 2013).

Axonal transport is dependent not only on the motors but on other conditions, for
instance the cytoskeleton. The neuronal cytoskeleton provides the structural integrity and
due to its dynamic properties, the neuron is also able to change morphology and grow
over time (Chevalier-Larsen and Holzbaur, 2006). The microtubules in the axon serve as
the tracks for transport by molecular motors; dynein and kinesins transporting various
cargo in the retrograde and anterograde direction respectively (Figure 3). The rapid
polymerization and depolymerization in microtubules is required for the axon and growth
cone earlier in the developmental cycle. This however is significantly reduced in the
mature neuron as the microtubules are stabilized more in part by microtubule associated
proteins (MAPs). These features of MAPs are vital in regulating transport in the axon
through the interaction of the molecular motors with the microtubules (Dixit et al, 2008).

Although these motors have significant differences structurally as well as in their
kinetics, experiments show that both kinesins and dynein’s are transported bidirectionally
suggesting a mechanism for the regulation of their functions (Hendricks et al, 2010).
Additionally, apart from cargo transported predominantly in one direction a number of
organelles are transported by both dynein and kinesin in both directions. Bidirectional
transport of cargo may involve the attachment of either dynein or kinesin molecules.
This ensures that each motor is available for respective movement and prevents the
situation where one motor will be stuck in one compartment of the cell and be unable to
12

move cargo when required. Kinesin–driven transport towards the synapse may
translocate mitochondria, synaptic vesicles, axolemma precursors (Elluru et al, 1995,
Leopold et al, 1992). Dynein is known to transport microtubules in neurons as
experiments interrupting dynein transport revealed that the microtubules are stuck at the
centrosome (Ahmad et al, 1998).
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Figure 3 Microtubule based intracellular transport
The molecular motors dynein and kinesin generate force within cells to transport various
cargo such as vesicles, signaling molecules, RNA and mitochondria utilizing
microtubules as tracks. The majority of kinesins move cargo away from the nucleus to
the minus end, whereas cytoplasmic dynein is responsible for retrograde transport
towards the nucleus.
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Dynein and kinesin transport neurofilaments which provide structural support to the axon
and dendrite and aids in the transmission of nerve impulses (Roy et al, 2000, Yuan et al,
2015). It has also been suggested that some neurofilament proteins offer stability by
interacting with synaptic proteins from the brain and peripheral synapses (Ralph and
Nixon, 2016). The movement of cytoskeletal proteins ie. microtubules, actin,
neurofilament is believed to be proceed at a much lower rate than organelle transport
(Baas and Buster, 2004). This is probably needed to allow remodeling of the
cytoskeleton at the growth cone, so that axons can be withdrawn if need be and
reorganization of microtubule polarity in dendrites.

In the developing neuron, dynein plays a role in neuronal migration via its interaction
with other binding partners. (Sasaki et al, 2000) showed that the Lis1, which is the
mutant protein in the neurological condition Lissencephaly or smooth brain, marked by
abnormal cortical layering in the brain and large ventricles interacts with dynein and
could possibly be a regulator of retrograde axonal transport. Neuronal migration defects
were also confirmed in a dynein mutant mouse model by Ori-McKenney and Vallee,
2011. Dynein was identified as part of the postsynaptic density (PSD) in the dendritic
spines of rats (Cheng et al, 2006). This finding in addition to what is already known
about the transport of synaptic components to the soma for recycling suggests a role for
cytoplasmic dynein in the set up and maintenance of synaptic connections. Furthermore,
synaptic plasticity is affected by the activity of dynein and kinesin motors via the
transport of specific components (Yagensky et al, 2016). Cargoes transported by dynein
aid in maintaining neuronal health and survival, for instance signaling molecules,
15

proteins to be recycled (Delcroix et al 2004, Susalka and Pfister, 2000). The clearing of
misfolded proteins helps prevent their eventual accumulation and/ or aggregation which
could have deleterious effects on the neuron. Signaling molecules could also be
transported as receptor –ligand complexes and are vital in the signaling pathway that
ensures survivals of neuronal cells (Harrington and Ginty, 2013).

(Yano et al, 2001) reemphasized the important role of dynein in the neurotrophic
signaling cascade when they reported the binding of dynein to the neurotrophic receptors
TrkA, TrkB and TrkC. Brain –derived neurotrophic factor (BDNF) is one such
neurotrophic factor known to control dendritic growth and morphology in cortical
neurons (McAllister et al, 1997). When BDNF mediated transport is perturbed by
dissociating dynein from the adaptor snapin, dendritic growth is reduced (Zhou et al,
2012). Dynein is also instrumental in the lysosome degradation pathway. The transport of
autophagosomes to the cell body by dynein allows them to mature as they acquire other
components en route. (Maday et al, 2012). Jip-1 and huntingtin, which are major players
in the transport of autophagosomes have been shown to associate with dynein and kinesin
(Fu et al, 2014).

There is growing evidence that supports the possibility of local protein synthesis in the
axon, which largely stemmed from the identification of components of the protein
synthesis apparatus (Steward and Levy, 1982, Giuditta et al,2002, Fumy et al, 2010).
Axonal protein synthesis can be typically observed when there is an injury and there is
the need to turn on biochemical and molecular switches to reprogram a growth cone for
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axonal regeneration (Yoo et al,2010). All of this means that mRNA and indeed
components of the translation machinery must be transported to the site of translation,
this is accomplished by dynein and kinesin activity (Zhang et al, 2001). Further
involvement of dynein in mRNA transport is seen with RNA granules, which are
complexes of mRNA plus other proteins that help target it to a specific location (Bassell
and Kelic, 2004). Stress granules contain ribonucleoproteins and enable the cell mount up
the appropriate response under harsh conditions like toxin exposure, elevated
temperature, and factor generally repress translation in one way or the other (Kedersha
and Andersen,2002). In spinal cord neurons subjected to arsenite stress, dynein was
discovered to be key not only in the composition of stress granules but equally in the
disintegration of the complexes as well. (Tsai et al, 2009. Loschi et al, 2009). Axonal
transport is central to a lot of the processes in the neuron that promotes its survival, and it
is also important in the pathology of neurodegenerative diseases as a whole; during both
the subtle and overt stages. Exploring how these diseases influence the intricate
interactions of motor proteins like dynein with different cargoes and accessory proteins
will be key to the development of effective treatment and management solutions.
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1.4

Charcot Marie Tooth Disease

Charcot-Marie-Tooth disease (CMT) is named after 3 neurologists, Jean-Martin Charcot,
Pierre Marie and Howard Tooth, who discovered it in 1886 (Daroff et al, 2012). The
disease also referred to as hereditary motor and sensory neuropathy (HMSN) describes
multiple inheritable motor and sensory neuropathies affecting various proteins (Figure 4.
Pareyson and Piscosquito, 2014). 1 in 2500 individuals are believed to be affected by
CMT disease (Nelis et al,1996), making it the most common inheritable peripheral nerve
disorder worldwide (Magy and Vallat, 2015). To date over seventy genes have been
implicated in the different types of CMT disease. Electrophysiological readings led to the
broad classification of the forms of the disease as either demyelinating (CMT1) and nondemyelinating (CMT2) or Axonal (El-Abassi and Carter, 2013). CMT1 involves
mutations in genes encoding myelin proteins or transcription factors for example
PMP222, MPZ, and CX32. When proteins that function in the maintenance of the axon
are affected, it is classified as CMT2. Some examples are CMT2B (mutation in the
KIF1B kinesin gene), CMT2B (mutation in RAB7) and CMT2E (mutation in
neurofilament gene NEFL) (Zhao et al, 2001, Meggouh et al, 2007, Mersiyanova et al,
2000). CMT disease reduces the quality of life of its sufferers since they have to deal
with limited mobility arising from distal limb weakness, deformity and pain. Some of the
common deformities include pes cavus, pes planus and hammer toes (Figure 5, Pareyson
and Marchesi, 2009, Tazir et al, 2014). Less common features like gait problems and loss
of sensation in the hands and feet can also impose further difficulty on patients. CMT
disease has a variable onset based on patient data and usually begins with muscle
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weakness and atrophy of the feet and then slowly advances to the upper limbs
(McCorquodale et al, 2016).

1.4.1

Diagnosis

Due to the heterogeneity of the phenotypes and variable onset in some cases, physicians
cannot rely heavily on family history. As a result, genetic testing has proved invaluable in
the diagnosis of CMT disease. Clinical evaluation may also involve investigating sensory
and motor symptoms, muscle strength in the arm and leg and nerve conduction velocities.
Advances in sequencing have proved useful with the use of DNA arrays, exome
sequencing and next generation sequencing in genetic tests.

Nerve conduction velocities (NCVs) above 38 m/s are classified as CMT2 whereas
demyelinating CMT1 NCVs are usually less than 38m/s. Mid-point values from 36-45
m/s are categorized as Intermediate CMT or X-linked CMT (Hoyle et al, 2015). Thus, the
electrophysiological test is needed to distinguish the demyelinating form from the nondemyelinating form to help inform the most appropriate treatment regimen. Research into
therapeutic options for the various forms of CMT diseases to a very large extent depends
on the genes or proteins involved and the cellular processes that are altered (Figure 4).
For instance, in animal models of CMT1A, vitamin C and progesterone antagonists have
been found to limit the expression of PMP22. These results however were not replicated
in human subjects (Sereda et al, 2003, Gess et al, 2015). Other strategies involve
targeting ligands, inhibitors or receptors involved in transducing signals downstream of
the affected genes. Targeting the genes of interest poses a challenge in subtypes of the
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disease with multiple mutations, like CMTD, where there are about 15 reported mutations
in the enzyme glycyltRNA synthetase (GlyRS) (He et al, 2011). Gene therapies
comprising the use of induced pluripotent stem cells (IPSCs), RNA antisense
technologies aimed at modifying gene expression could provide more promising
outcomes. More extensive research is required regardless of the strategy, to move these
remedies successfully from the pre-clinical to the clinical phase.

1.4.2

Management

Clinically, physical therapy and exercise are commonly employed in managing the
associated symptoms of CMT disease. Gait, balance and posture can be corrected after
consistent application so that the risk of injury or fall is greatly reduced. These exercises
are helpful in reducing the stiffness in affected muscles and can be important in
preventing deformities in the limbs later on in life. (Mathis et al, 2015). Some ankle and
foot deformities such as pes cavus and hammertoes require surgical interventions due to
their severity. Physical and occupational therapists offer assistive or orthotic devices such
as special shoes, braces, crutches and canes to ease mobility in patients (Bird, 2016).
Orthoses can help provide extra support to the local site affected and compared to
surgical procedures, serve as simpler, non-invasive procedures to manage the cognate
symptoms of CMT disease. In designing physical activities for neuromuscular disease
patients, it is highly recommended to start with low-intensity exercises rather than high
intensity regimens (Abresch et al, 2012). This allows relief and/or recovery to occur at a
steady pace over a period of time without compounding the symptoms.
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Figure 4 CMT target genes affected and cellular processes involved
Many genes account for CMT disease phenotype. Mutations affecting proteins in the
Schwann cell are classified as the demyelinating form of CMT, while those affecting
axon and cell body proteins fall under the non-demyelinating category of CMT disease
(Jerath and Shy, 2015).
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Figure 5 Classical features of Charcot Marie Tooth Disease
CMT disease impairs ion of motor and sensory nerves resulting in a range of phenotypes
that mainly affect the lower limbs and the hands in some cases. (a,b)Atrophy of the
muscle in the lower limbs, (c) pes cavus (d) hammertoes, (e) callosities of the foot and (f)
claw hands (Pareyson et al, 2009)
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Efforts directed towards pharmacological interventions have not been so successful, for
example initial findings about ascorbic acid for the treatment of CMT1A looked
promising but actual data from patients did not show much improvement in their health
(Visioli et al, 2013). The plant –derived curcumin compound that is known to have
multiple therapeutic effects was found to boost the production of Schwann cells by
reducing myelin protein zero protein misfolding (Patzko et al, 2012). Mice bearing
mutations in the heat shock protein HSPB1 recorded modest improvements in some
symptoms when histone deacetylase 6 (HDAC6) inhibitors were administered. HDAC
inhibitors alter the transport defects through tubulin deacetylation (d'Ydewalle et al,
2011). In CMT1A rats, there was an observed amelioration of the disease phenotype
when a progesterone antagonist, onapristone was administered. Onapristone reduces the
levels of the Pmp22 gene which is normally overexpressed in CMT1A disease (Sereda et
al, 2003). However, onapristone could not be used in humans due to its toxicity,
prompting the need for further studies into alternative progesterone antagonists
(Shy,2006). Going beyond just CMT1A, scientists are looking into different strategies
and approaches to find remedies that can work in humans. One example of such is a
massive drug screen involving 3,000 drugs in a high throughput screen that led to a
shortlist of 9 with significant activity against different targets. More toxicity studies
excluded 5 of them, leaving just 4 suitable compounds (Jang et al, 2012). Although this
screen was specifically targeting modulators of myelin genes it is worth looking into for
other forms of CMT disease.
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Dietary supplements like some essential fatty acids, vitamin E as well as the drug 3, 4diaminopyridine have been experimented as treatment options, but once again they are
not backed by convincing data in patients (Williams et al, 1986 & Russell et al, 1955).
One major challenge that has hampered the search for remedies in the past has been the
absence of adequate historical records on the disease. This is because sometimes
symptoms are observed late, as the disease progresses slowly. Also,it is possible patients
were previously misdiagnosed when parameters were not clearly defined. This has been
addressed to some extent with the emergence of focused groups like the INC
(International Neuropathies Consortium) which are working hard to collate data on
patients (Gutman and Shy, 2015). Another initiative to ensure success in dealing with
CMT disease is to encourage collaboration among health experts; neurologists,
geneticists, physiatrists and orthopedic surgeons to provide more holistic care and to
possibly give patients a better quality of life. (McCorquodale et al, 2016). Such
collaborative efforts facilitate data sharing and enables providers monitor disease
progression and patient recovery more closely.

1.5

Skeletal Muscle Function

Voluntary movement in the body is achieved through striated cardiac and skeletal
muscles (Kho et al, 2012). Skeletal muscles attach to the bone via connective tissues and
are responsible for the movements of bones at a joint. Skeletal muscles therefore possess
tensile and contractile properties that enable them to support movement. These are made
possible by a myriad of cytoskeletal and structural proteins that are well regulated with
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coordinated functions to obtain the proper assembly. Sheets of connective tissue known
as fascicles, cover multiple muscle fibers organizing them into bundles. Skeletal muscles
have numerous nuclei, distinguishing them from other cell types. However, they possess
organelles such as mitochondria, endoplasmic reticulum, and glycogen granules just like
other cells in the body (Fox, 2011).

1.5.1

Muscle Sarcomeres

Sarcomeres are the units of contraction in skeletal and cardiac muscle (Goulding et al,
1997). The highly ordered patterns account for the striations in these muscle types. The
proper assembly of various proteins into the final ordered structure is indispensable in the
maintenance of proper muscle structure and function. The components of the sarcomere
appear as bands or lines under the microscope. There are 4 main components of the
sarcomere; Z-line, I-band, A-band and M-line (Figure 6). The Z-line delineates the
sarcomere and consists of proteins such as alpha-actinin, capZ, desmin and myotilin that
serve as attachments of the thin filaments. The I-band is made up of mainly actin and
other associated proteins including troponin, tropomodulin and nebulin. The region
consisting of mainly thick myosin filaments and thin filaments is referred to as the Aband. Contraction of the muscle occurs when the sarcomeres shorten due to the sliding of
the myosin filaments over actin. (Cadot and Gomes, 2016). At the center of the A-band,
are a group of specialized proteins belonging to the myomesin family that make up the
M-line or M-bridge (Henderson et al, 2017). These function to provide stability to the
myosin heavy chain and in sensing and transducing intracellular signals.

The highly ordered sarcomere lattice would suggest a fixed, rigid structure, however, it
can undergo reorganizations in response to different cues like stress or injury.
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1.5.2

Myonuclei and Muscle Development

Skeletal muscle fibers are characterized by numerous nuclei and units of contraction
known as sarcomeres in tandem which account for the striations. The muscle nuclei are
maintained over a range of specific internuclear distances possibly to mark out domains
for more efficient transcriptional control (Bruusgard et al, 2003, Pavlath et al,1989).The
debate as to whether nuclei number is related to the size of the muscle fiber is still pretty
much unresolved, especially when it has been observed that increase in muscle size is not
always accompanied by a large presence of myonuclei (Verheul et al,2004; Aravamudan
et al, 2006). Progenitor cells in the muscle known as satellite cells are positioned between
within the basement membrane and sarcolemma. Their location within the vicinity of
myonuclei at the periphery, likely enhances the replacement of damaged nuclei in the
event of an injury (White et al, 2010). The maintenance of a maximum number of nuclei
marks the attainment of maturity in the muscle and is necessary for muscle functioning
(Davis and Fiorotto, 2009). This makes satellite cells therapeutic targets for the treatment
various neuromuscular disorders if their regenerative capacity can be harnessed. There
are several factors that influence proliferation in satellite cells; muscle type, age and
chemical modulators (Manzano et al, 2011). Testosterone for instance, enhances the
proliferation of satellite cells and increases muscle nuclei abundance in rats (Joubert
&Tobin, 1989). The satellite cells maintain an actively dividing population during
development, and a smaller population that stays in a quiescent mode. The larger
proliferating group is high in numerosity and most active during early postnatal days
accounting for the high cell number, after which both number and activity decline in
adulthood (Neal et al, 2012).
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Nuclei positioning is very important for the normal functions of the muscle fiber,
conversely, the misalignment of the nucleus is linked to disorders of the muscle
(Gueneau et al, 2009, Romero,2010). Molecular motors, microtubules and a host of
adaptors and regulators are responsible for the placement of nuclei in different cell
systems. Work done in the muscles of Drosophila points to joint roles by both dynein and
kinesin in positioning nuclei (Folker et al, 2014). This study proposed a mechanism with
segregated roles for the motors where their ability to generate force is harnessed at
leading and trailing ends of the migrating nuclei. In mutant Drosophila embryos with
impaired dynein and kinesin function, changes occurred in the shape of the nuclei and the
pace of myonuclei transport was much slower.
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Figure 6 Illustration of the contractile unit of the muscle
Long tubular structures called myofibrils make up each muscle fiber, and these
myofibrils possess repeating sarcomeres. The distance from one Z-line to the other
represents the length of one sarcomere. Thick and thin filaments overlap on the A-band.
The I-band has only thin filaments and the H-zone only has thick filaments whose center
is marked by a group of proteins constituting the M-line.
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Figure 7 Nuclei placement in muscle fibers
Muscle fibers stained in red and DAPI-stained nuclei (blue) from a wild-type mouse
muscle tissue. Nuclei are normally positioned at the periphery of the muscle nuclei based
on the need to maintain transcriptionally controlled sections within the fiber. When there
is some muscle pathology, the arrangement could be disrupted leading to the presence of
more centrally-positioned nuclei within the muscle fiber.
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1.5.3

The Neuromuscular Junction

The neuromuscular junction (NMJ) is a peripheral synapse that maintains the connection
between the motor neurons and muscle fibers. This connection ensures that action
potential initiated by the nerves are carried across to ensure contraction of the muscle
(Tintignac et al, 2015). The formation and maturation of the NMJ consists of a myriad of
molecular events that are well regulated and coordinated by key players. This multitiered
set up also makes it vulnerable to disease at diverse levels when the normal functions are
disrupted. Disorders of the peripheral nerves such as Charcot Marie Tooth Disease,
SMAs, myasthenias and muscular dystrophies usually affect the neuromuscular junction,
making it important in understanding the pathology and progression of disease. Mutations
that affect signaling pathways that control the maturation and stability of the synapse or
the withdrawal of nerve inputs can all interfere with the normal functioning of NMJs and
lead to muscle weakness, fatigue, atrophy and paralysis in very severe cases (Ferrraro et
al, 2012). The setup of the peripheral synapse begins with motor axons making contact
with their muscular target once the myotubes fuse to form the myoblasts. (Lin et al, 2001)
observed that majority of the AChRs are innervated by E13.5, with complete innervation
of all AChRs achieved by E16.5. Transmission at the synapse occurs once the growth
cones of the motor axons reach the myotubes. The NMJ at this point is functional and is
characterized by having multiple inputs from a number of axons at the time of birth.
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Figure 8 The developmental timeline of neuromuscular junctions in mice
Motor neurons contact muscles by E12.5 after the myoblasts fuse to form myotubes.
Terminal Schwan cells start move towards the end-plate some time before E15. Acetyl
choline receptors also cluster as the axons approach the myotubes. One of the most
significant changes that occurs afterwards is the shift from poly-innervated muscle fibers
to single innervated fibers beginning from birth to P14. (Bloch-Gallego, 2015)
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1.5.3.1 Synapse Maturation
The most noticeable feature is the change in shape or morphology of the post-synaptic
apparatus, from a solid plaque to a highly-branched structure commonly referred to as the
‘cookie to pretzel transformation’. The end plate, which was previously flat is elevated to
form gutters or troughs. There is also an increase in other cellular components at the end
plate which help make it more stable, some of these include the basal lamina and various
cytoskeletal proteins. The AChRs undergo a change in Ca permeability that favors the
initiation and generation of action potential. Similarly, the ion and ligand gated channels
are also reorganized to achieve the same purpose. Structural changes occur as the AChRs
mature; the most significant is the replacement of the γ – subunit to an ε- subunit. The
morphology of AChR clusters at the endplate also changes during maturation. Nerve
inputs are withdrawn till the end plate has just one input. The transition from an immature
polyinnervated apparatus into the fully-developed form in the adult is responsible for the
rearrangement of AChR structure (Figure 8. Sanes and Lichtman, 1999). Further changes
occur as the muscle fiber increases in surface area due to growth. The invaginations that
develop are typically about 1um deep and are spaced at 3um from one another. The
AChRs located on the crests of the folds are as a result easily accessible to the nerves.
Another major change in the mature post-synaptic apparatus is the subunit change that
occurs in the AChR. One subunit out of the pentamer (α2βδγ), specifically the γ-subunit is
traded for an ε-subunit (α2βδε) to make the receptor more stable (Missias et al, 1996,
Sanes and Lichtman, 2001).
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1.5.3.2 Transmission of Nerve Impulses
Innervation of the muscle by motor neurons is critical for normal functioning and
structural development of the peripheral synapse. The innervation precedes the cascade of
molecular events that occur to ensure the proper development and maturation of the NMJ.
In a functional neuromuscular synapse, the transmission of signals in the post-synaptic
compartment is facilitated by a surge in the number and density of acetyl choline
receptors at the end plate. The acetylcholine receptors (AChR) can accumulate up to over
10,000µm2 in density in the synaptic zones. This number is vastly different from regions
farther away where the density is approximately 10µm 2 (Sanes and Lichtman, 1999).
Subsynaptic nuclei located beneath the receptors are partly responsible for this
phenomenon. These nuclei positioned at the NMJ in clusters of between 3- 8 nuclei
maintain a transcriptional profile distinct from nuclei outside the synaptic region and
transcribe genes needed for the developing NMJ (Simon et al,1992, Briguet and
Ruegg,2000). The reorganization and specification that occurs in and around the synaptic
region is achieved via three pathways. Agrin is released by the nerves and it binds to the
muscle specific receptor tyrosine kinase (MuSK) present in the muscle. This leads to
other downstream events that result in the clustering of acetyl choline receptors.
Preferential expression of AChR genes in the synaptic nuclei also occurs and this is
mediated by neuregulin and erbB kinases. The upregulation in transcription of AChR
genes requires the suppression of gene expression in regions outside of the synaptic
region. Acetyl choline binds to AChRs to trigger the influx of calcium and the generation
of a voltage –dependent signal to down regulate the expression of genes. The nerves were
initially thought to be required for clustering of the acetyl choline receptors in the initial
stages of development. (Lin et al, 2001) examined neuromuscular junction development
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early at E14.5 and identified a concentration of AChRs, suggesting that neural cues may
not be needed to initiate NMJ development. This observation confirmed what was
previously reported by other researchers (Lupa and Hall, 1989 & Dahm and Landmesser,
1991). Experiments with mutations in the MuSk show it is a major player in the neuralindependent post synaptic organization seen early in development. That notwithstanding,
the nerve input is required for further development and maintenance of the
neuromuscular junction. The involvement of the MuSK pathway in initiating synaptic
differentiation help explains why mice lacking the receptor die at birth, and why
mutations lead to congenital myasthenic syndrome in humans (Dechiara et al, 1996 and
Chevessier et al, 2004). MuSK depends on agrin binding to dimerize and activate its
kinase activity. Further downstream, other kinases responsible for the phosphorylation of
the AChR subunits are also activated. A membrane protein which associates with the
AChRs known as Rapsyn or Receptor-associated protein at the synapse is vital in AChR
clustering. Studies into the precise function of Rapsyn indicate that it is required for
phosphorylation of AChRs. The cytoskeleton is another crucial factor in triggering AChR
clustering. The MuSK-agrin path way mediates the positioning of the receptors on actin
filaments after they have undergone some rearrangements. This process may be important
to provide additional stability to entire post-synaptic apparatus (Strochlic et al, 2005).
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1.5.4

The Role of Glial Cells at the Neuromuscular Junction

The peripheral synapse is a tripartite system consisting of the motor neuron, acetylcholine
receptor and perisynaptic Schwann cells (PSCs) also known as terminal Schwann cells.
Details about the exact functions and mechanisms of these specialized Schwann cells
located at the synapse are still being uncovered. The glial cells associated with the
peripheral synapse differ from myelinating Schwann cells in many ways: the most
obvious being location with the PSCs covering the nerve terminal and the myelinating
Schwan cells wrapping around the axon further upstream, accounting for saltatory
transmission of nerve impulses. Both myelinating and non-myelinating Schwann cells
share similar proteins or markers such as myelin-associated glycoprotein, myelin protein
zero (MPZ), galactocerebroside and 2′,3′-cyclic nucleotide-3′-phosphodiesterase
(CNPase) (Feng & Ko, 2008). Mature PSCs however uniquely express genes not found in
myelinating glia such as LNX1, an E3 ubiquitin ligase (Young et al, 2005) and Nav 1.6
(Musarella et al, 2006). These biomarkers have proved very useful in the investigation of
PSCs and their effects on NMJ development. PSCs possess more neurotransmitter
receptors and ion channels in addition to receptors for ATP and acetylcholine. They also
produce chemicals like nitric oxide, prostaglandins and glutamate, which regulate
synaptic communication (Auld et al, 2003). The density of PSCs at the NMJ significantly
increases as the animal progresses to adulthood, possibly in response to roles in the
maintenance and proper functioning of the synapse (Love and Thompson, 1998).
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Figure 9 Glial cells at the neuromuscular synapse
Non-myelinating glial cells, also known as terminal Schwann cells (stained in red) are a
part of the tripartite apparatus of the peripheral synapse. Terminal Schwann cells play a
role in the maintenance of NMJs and guide resprouting axons to their target.
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1.5.4.1.1 Roles of PSCs in the developing NMJ
PSCs and axons make their way early to the muscles at about the same time in the
developmental timeline. There is evidence to show that although the nerves still
successfully associate with muscles, they are significantly defasciculated when PSCs are
ablated (Suguira and Lin, 2011). Whilst the axons may not need the PSCs to locate their
targets, they start to retract when the PSCs are depleted from the NMJ. Thus, PSCs may
rather be important in maintaining the neuromuscular synapses through various means.
PSCs were found tightly associated with the AChR dense areas in developing NMJs up to
14 days after birth. More probing revealed how they assist in input removal through the
phagocytosis of nerve terminals (Smith et al, 2013). This is explained by the ability of the
PSCs to sense the strength of synaptic inputs from incoming nerves at polyinnervated
NMJs (Jahromi et al, 1992; Darabid et al, 2013). Researchers have been interested in the
molecular switches that regulate the PSCs in the course of development and how that
affects neuromuscular function as a whole. ErbB2 is a tyrosine kinase receptor which acts
downstream of neuregulin and is normally found in Schwann cells and muscles during
NMJ development. Studies with erbB2 deficient mice revealed not only aberrations in
NMJ development but the loss of Schwann cells at nerve terminals of developing
embryos. The mice also die at birth most likely because of breathing difficulties caused
by neuromuscular anomalies in the diaphragm (Lin et al, 2000). The removal of PSCs
adversely affects neuromuscular junction development as the nerves of the muscle retract
and the motor neurons degenerate (Wolpowitz et al,2000).
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1.5.4.1.2 Roles of PSCs in the mature NMJ
A lot of what is now known about PSCs came from studies with frogs (Rana pipiens),
although they differ from rodents in many ways. In frogs, the PSCs extend long
projections into the synaptic area and the amphibians PSC is maintained in a dynamic
state and are actively involved in transforming the entire NMJ structure, this contrasts
with the relatively more stable set up in mammals (Ko and Robitaille, 2015). Injury or
damage to the nerve also triggers the phagocytic activity of the PSCs. This process clears
debris and guides axons to reinnervate the muscles. Through a similar mechanism, PSCs
isolates surrounding connective tissue and basal lamina when there is an injury, or even
when the axon is severed. The axon is unable to initiate its own regeneration and depends
on the PSCs and other key players to make contact again with target cells. In the
Schwann cells of both adult frogs and rodents, there are receptors for the binding of Ca 2+
and ATP (Parinello et al, 2010). The presence of muscarinic and purinergic receptors in
PSCs makes it possible to modify Ca levels and ultimately the expression of specific
genes. PSCs generally influence NMJ structure and function often with the input of
upstream signals. Neuregulins, for instance via the erbB kinases trigger changes in the
Schwann cells that maintain efficient synaptic transmission and stabilize motor terminals
(Trachtenberg and Thompson, 1997). PSCs produce neuronal factors that stimulate a
cascade of downstream events. Neuregulin-2, required for transcription by acetyl choline
receptors and agrin, an inducer of receptor aggregation, are expressed by PSCs (Yang et
al, 2001, Rimer et al, 2004). It is safe to speculate that expression of these factors allows
the maintenance of the NMJ to continue even after maturity, or it may be a backup
mechanism during denervation or neuronal injury.

38

1.6

Animal Behavioral Assays

The use of standardized protocols to examine the phenotype of animals with mutations
has become valuable in establishing disease model systems and in translational research.
These protocols allow the mutant animal to be pathologically characterized to either
confirm or rule out the existence of disease. The benefits of standardized phenotypic
assessment of animals include the possibility of differentiating spontaneous and induced
mutations, strains of animals and analyzing the impact of transgenic or genetically
manipulated models of disease (Rogers et al, 1997). There are certain conditions that
must be generally satisfied regardless of the specific application of behavioral
assessment. It is vital to avoid partiality by keeping benchmarks for all groups, and these
include but are not limited to, initial time point and endpoint, features or characteristics to
be examined, a scoring system if needed and an accurate record keeping system
maintained for all tests carried out. Behavioral assays also cover observations on the
morphological characteristics of the cohort; body mass, body length and notes on the
functional activities as well. An often-used well-designed system for behavioral testing is
the SHIRPA analysis (Rogers et al,2001). This comprises a protocol involving three
stages of screening to assess neurological impairments in an animal. This can be very
useful in cases where it is not possible to predict exactly which system will be affected
for instance, whether there is more of a sensory deficit or a cognitive deficit in the case of
neurological disease models. The initial screen of SHIRPA is based on observation of the
general health of animals for features like hair color, gait, posture, excitability,
aggression, defecation, salivation etc. It is a general analysis that also requires a scoring
system to properly document findings. The next level of screening is more detailed and
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targets an underlying pathological condition. Motor performance, balance and
coordination and nociception are some of the measurements that can be taken and these
can be done with the appropriate measuring device or equipment. Histopathological
procedures, biochemical analysis of plasma or serum for metabolic investigations are
done at this level of analysis. The third of level of screening is custom-made for a known
condition that does not necessarily require a battery of assays to establish the presence of
a phenotype. At this stage investigators will be interested in defects of a cognitive or
psychiatric nature. The assays are usually for more specific conditions, anxiety for
instance can be measured with the open-field activity test, elevated maze or light-dark
box; learning and memory defects can be examined with the Morris water maze. At this
final stage of screening some other techniques like nerve conduction, electromyography,
electroencephalography and magnetic resonance imaging could be utilized.

The reproducibility of behavioral data is important like in any other assay for that matter,
for that reason it is important that the environment in which these tests are carried out are
carefully controlled to limit sources of variation. Concerns about a valid environment are
validated by data suggesting interactions between genes and external factors in the
environment (Gottlieb, 1998). The environmental conditions are within the power of the
investigator as well as associated parameters as standard equipment, protocol, husbandry
conditions etc. These as potential sources of variability can be eliminated by
standardizing experimental parameters for all test groups. The situation is quite different
from more intrinsic factors that have to do with the neighboring genes where the mutation
is found and the effects that could arise from using a strain of the organism or animal
from a particular genetic background (Wahlsten, 2001).
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Figure 10 Examples of behavioral assays used in assessing motor phenotype in mice
A) The rotarod is useful for determining motor coordination B) The grip strength meter
records the muscle strength C) The tail suspension assesses hind limb posture as a reflex
response when mice are suspended by the tail D) The suspended pole tests balance and
muscle strength E) foot print assay is for gait analysis F) the wire mesh tests balance and
muscle strength in the limbs of mice
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Records of past experimental procedures from literature are a good starting point in other
to pick a particular background for genetic manipulation. It might be just easier to
maintain the same genetic background for a related mutation. A lot of pointers can be
obtained from research geared at ascertaining the effects of multiple factors on the
accuracy of behavior data. They can help inform an investigator on the experimental
design or choice of assays. (McIlwain et al, 2001) in one such study, looked at the effects
of serial testing (using different assays) on mice and whether or not the sequence of the
assay also had any effects on the output. There were both similarities and differences in
mice that performed single assays versus those that did multiple assays. There were
however fewer differences resulting from the order of assays when two groups of mice
were compared. Deductions from studies of this nature always require caution, after the
factors are meticulously examined. In making decision regarding an experiment, every
investigator must pay attention to the results obtained making use of relevant statistical
tools and analysis to scrutinize the data obtained in several ways to erase doubt.

The choice of a behavioral test is obviously made based on the expected phenotype of the
animal, and as such the right tool or equipment for the assay has to be picked as well.
Regarding the equipment, it is possible to design an apparatus that achieves the same goal
with certain tests thereby save cost from not purchasing an automated device (Figure 10).
There are number of advantages with an automated system compared to non-automated
ones. Scores can be done more accurately, and this enhances the chances of data
reproducibility, the investigator or tester interferes very little on the process, it can be
more efficient and drastically reduces the expense of energy (Hanell and Marklund,
2014). The caveat however with an automated procedure is to find ways of verifying the
42

data, making sure it makes sense and satisfies metrics like trends and normal distribution.
It may be therefore helpful to consider the level of automation, in such circumstances a
process that is almost completely automated would necessarily analysis of the output data
to ensure that it makes scientific sense.
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CHAPTER 2:MATERIALS AND METHODS

2.1

Generation of DYNC1H1 H304R Knock-in Mouse Model

An 8.04 kb region used to construct the targeting vector was subcloned from a positively
identified C57BL/6 BAC clone (RP23:60K23). The BAC was subcloned into a 2.45 kb
backbone vector (pSP72; Promega) containing an ampicillin selection cassette for
retransformation of the construct prior to electroporation. The region was designed such
that the long homology arm extended 5.3 kb 5′ to the point mutation (A to G) in exon 5 A
pGK-gb2 FRT NeoR cassette was inserted into the gene in intron 5–6. The short
homology arm extended 2.05 kb 3′ of the FRT-flanked Neo cassette.
The CMT2O mutation CAC to CGC (mouse aa304: His to Arg) within exon 5 was
generated by 3-step PCR mutagenesis. Four primers, PT1 – 3 and LUNI, were designed
and used to amplify a ∼2.5 kb fragment that incorporated the mutation at the desired
position. The point mutation was engineered into primers PT2 and PT3. The final PCR
fragment carrying the point mutation (middle arm) was then used to replace the wild-type
sequence using conventional sub cloning methods at an endogenous enzyme site, MfeI,
and at a MluI site in the Neo cassette. The targeting vector was confirmed by restriction
analysis after each modification step, and by sequencing using primers designed to read
from the selection cassette into the 3′ end of the middle arm and the 5′ end of the SA.
Sequencing showed the presence of the mutation and that no errors were introduced in
the PCR amplified region (Sabblah et al, 2018).
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The targeting vector was linearized and electroporated into C57BL/6 × 129/SvEv hybrid
embryonic stem cells. After selection by G418 resistance, surviving colonies were
expanded and screened for recombinant clones by PCR using primers LAN1 and A1.
Positive clones had the presence of the point mutation confirmed by a second round of
PCR screening using primers SQ1 and LUNI followed by sequencing of that PCR
product. Integration into the correct genomic location was confirmed by southern blot
analysis. Three clones were confirmed as integrated into a parental chromosome at the
targeted site and were then used for implantation (Sabblah et al, 2018).
Positive stem cells were microinjected into C57BL/6 blastocysts. The blastocysts were
transferred to pseudopregnant foster mothers and chimeras were obtained. Those
chimeric mice were crossed to mice constitutively expressing Flp recombinase to produce
F1 heterozygous knock-in targeted, NeoR cassette deleted mice. PCR was used to
confirm the deletion of the Neo cassette and sequencing of the four founder mice
confirmed the presence of the point mutation (Sabblah et al, 2018).

2.2

Mouse Breeding and Colony Management

Four founder animals (F1) with the confirmed H304R/+ mutation from InGenious
Technologies were crossed to Jackson Laboratory mouse hybrid strain, C57Bl6/129
(Stock # 101045) generating wildtype and H304R+/R mice. The animals were out
crossed to the C57Bl6/129 strain up to the F7 generation. The progeny of these mice were
used to breed the behavioral group for this study. Animals were bred in pairs and/or trios
for behavior and tissue harvest. Founder females were bred with one male whereas
founder male was bred with either one or two Jackson wildtype females. Females were
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checked for pregnancy twice/ week. Males were housed singly for one week prior to
breeding. Females were housed in pairs or groups until paired with a male. Females that
did not produce a litter after three matings were removed from the breeding pool. Both
males and females were bred from 6-8 weeks old. Males were retired from breeding after
1 year and females were retired from breeding after 6 litters or 5 months whichever came
first. The animals were housed in microisolation cages with ad libitum access to food and
water under controlled temperature (22±2 °C) and humidity (50±10%) and maintained on
a 12-hour light/dark cycle. All mice were given red housing for environmental
enrichment (Sabblah et al, 2018).

All females were examined for plug positivity and the males were removed. The pups
were weaned on post-natal day 21. The animals were uniquely identified by tail tattoo
using SoMark Tail Tattoo system (SoMark Innovations, San Diego, CA). Tail snips were
taken at the time of tattoo. The tail snips were genotyped using PCR to determine the
genotype of the animals.

Western blot analyses were performed to determine if the H304R mutation altered the
amount or stability of dynein molecules in brain tissue. Brain tissue from wild-type and
H304R/+ male mice was homogenized in 35 mM PIPES pH 6.96, 5 mM MgSO4, 1 mM
EGTA, 0.5 mM EDTA supplemented with 1 mM dithiothreitol, 0.2 mM ATP, and a
protease cocktail. A high-speed supernatant of each sample was generated by spinning
the samples in an SW50.1 rotor for 30 minutes at 40,000 rpm. The samples were run on
SDS-PAGE gels, blotted and probed using standard techniques, utilizing antibodies
against dynein intermediate chain (clone 74.1, BioLegend) and glyceraldehyde-3-
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phosphate dehydrogenase (clone O411, Santa Cruz Biotechnology) as a loading control
(Sabblah et al, 2018). Signal was detected using goat anti-mouse secondary antibody
conjugated to horseradish peroxidase (Invitrogen) and the ECL Prime Western Blot
Detection Reagent (Amersham). Signal was captured on X-ray film and quantified using
NIH ImageJ software (Sabblah et al, 2018).

2.3

Motor behavioral assays

Mice were given motor skills behavior tests every two weeks beginning at 1 month of
age. The researchers performing the behavioral tests were blinded to the genotype of the
mice they were examining, and the mice were only identifiable by tail tattoo codes. The
tail suspension test was performed by gently lifting a mouse by its tail for 15 seconds.
The test mouse was recorded from both ventral and lateral angles to fully capture the tail
suspension reflex. The recorded tail suspension videos were then analyzed, and each test
was scored into one of two categories: typical or atypical response. Mice exhibiting a
typical response had their hind limbs splayed apart from each other and held away from
the body (Chen et al, 2007). In an atypical response, mice hind limbs were clenched
together and held either away from or near the body. The categorical tail suspension data
for mice of different genotypes were binned in three-month intervals and statistically
compared using the Fisher’s exact test (two-tailed distribution).

The accelerating rotarod test utilized an instrument (IITC Life Science, model# 755)
programmed to start at 5 RPM, ramp to 40 RPM over 60 seconds, and then maintain 40
RPM speed for a total time of three minutes (Sabblah et al, 2018). The elapsed time until
47

the mouse fell off the rotating rod was automatically collected with the Series 8 software
provided with the instrument (Hennis et al, 2013). Each mouse performed three
successive runs and these 3 readings were averaged for each test day. Each test mouse’s
averaged rotarod reading from test days was averaged again for 3-month bins. The wildtype and H304R/+ binned rotarod datasets were statistically compared for 3-month bin
using the two-tailed Student’s t-test (Sabblah et al, 2018).
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Figure 11 Parameters for the motor coordination assay
After a series of trials with different parameters, the optimized conditions for our motor
coordination assay on the rotarod were as follows: a speed of 5 to 40 rpm with a ramp
time of 60 seconds over a total duration of 180 seconds.

49

The limb muscular strength of mice was measured with a digital grip strength instrument
(BIOSEB Research Instruments, model# BIO-GS3). Each test mouse was placed on the
steel grid attached to the instrument and the grip strength reading was collected as per the
manufacturer’s protocol. The manufacturer’s RSIC software recorded the maximum force
(in grams) exerted by the mouse on the steel grid. The grip strength in the front two limbs
and all four limbs were measured for each test mouse (Mandillo et al, 2008). Mice could
not grip the instrument solely with hind limbs, preventing the direct assessment of hind
limb strength. All the grip strength measurements were taken in quadruplicates and the 4
reading were averaged on each test day. Each test mouse’s averaged grip data from test
days was averaged for 3-month bins. The wild-type and H304R/+ binned grip datasets
were statistically compared using the two-tailed Student’s t-test.

2.4

Tissue Preparation

Animals were anesthetized via intraperitoneal injection with SomnaSol ™ (7.5 mg/kg,
Henry Schein, Dublin, OH, USA). Cardiac perfusion was performed using 25 mls of
0.9% Saline (Hospira, Lake Forest, IL, USA) and then 4% paraformaldehyde (SigmaAldrich, ST Louis MO, USA). Gastrocnemius muscles were carefully dissected from
animals and kept in 4% paraformaldehyde (Dequen et al,2008). The muscles were
transferred into 30% sucrose for cryopreservation overnight at 4 oC. Muscles were
embedded in OCT Compound in plastic cryomolds (Sakura Fine Tek, Torrance, CA,
USA) and stored at -80 oC until ready for sectioning. 20 µm sections were obtained from
muscles using a cryostat (Leica CM1850) and attached to Superfrost Plus slides (Fisher
Scientific, Pittsburgh, PA). Fixation was done by immersing slides in acetone for 20
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mins at room temperature. The slides were then stored at -20 oC until ready for staining
and imaging (Sabblah et al, 2018).

2.5

Immunohistochemistry and Imaging

For neuromuscular junction analysis cryosections were first washed with PBS for 10
minutes each to clear out the OCT. The edges of the sections were marked with a PAP
pen to restrict the staining solution. Sections were then permeabilized for 10 mins with
0.5% Triton X100 and blocked for up to three hours in 5% bovine serum albumin and
goat serum with 0.1% TritonX100 in PBS at room temperature. Staining was done in a
humidified chamber with antibodies against neurofilament (2H3, DSHB and chicken NFH, EMD Millipore). The sections were washed three times with block solution for a
duration of 10 mins each. Alpha subunits of Acetylcholine receptors (AChRs) and
neurofilament were stained with the appropriate Alexa Fluor secondary antibodies (goat
anti-mouse 546, goat anti-chicken, 546, 488 alpha-bungarotoxin, Life Technologies,
Eugene, OR, USA). Two washes were first done with block solution for 10 minutes each
and then two final washes with PBS for 10 minutes each time. The sections were
mounted in antifade reagent containing DAPI (Life Technologies, Eugene, OR, USA) to
stain the nuclei. Images of neuromuscular junctions were obtained using a Zeiss LSM
710 Confocal microscope (Sabblah et al, 2018).
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Figure 12 Determination of Innervation using Image J Software
A schematic representation of the steps involved in determining innervation at the NMJ
as well as the appropriate plug-in to use
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2.6

Analysis of NMJ Architecture

Stacks obtained from confocal imaging were processed further using ImageJ for analysis
of innervation patterns and acetylcholine receptor (AChR) architecture (Figure 12).

The 3D Viewer plug-in was used in determining innervation at the NMJs (Schmid et al,
2010). The respective channels corresponding to neurofilament and AChR staining are
merged prior to applying the plug-in. The plugin enables rotation of the reconstructed
confocal image to examine the degree of innervation from different angles, this is useful
to find out whether the nerve occupies the post-synaptic region or not.

The 3D object counter was used to measure the volume and surface area of the AChRs
(Figure 14). The image is prepared by ‘smoothening’ to reduce noise and applying a
binary mask so that the images appear black against a white background. The threshold is
then be set to exclude objects that are outside the region of interest.

We utilized another set of plug-ins; Skeletonize 2D/3D and Analyze Skeleton 2D/3D to
generate a single line version of the image and evaluate different indicators of the
resulting structure (Figure 13, Arganda-Carreras et al, 2010). These indicators constitute
the complexity parameters used in characterizing the AChR’s (Table 1). We obtained
counts of branches, junctions, triple points, end-point voxels and slab voxels. The
program also calculates the average branch length, maximum branch length and longest
shortest path. The student’s T-test was used to determine the statistical significance of the
data obtained.
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Figure 13 How to analyze skeletons of the NMJ structure
Diagram showing how to process confocal images into skeletonized images and obtain
analyses that characterize the complexity and morphology of the NMJ
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Figure 14 How to measure surface area and volume of AChRs
The schematic outlines how to process image stacks from the confocal image to obtain a
calculation of the surface area and volume.
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Table 1 List of Complexity Parameters Used in Characterizing Neuromuscular
Junction Architecture
Parameter

Definition

Branches

The number of elongated segments in the skeletonized NMJ that link a junction point to
the nearest junction or end point.

Junctions

The number of vertices in the skeletonized NMJ that connect two or more branches.

Triple points

The number of vertices in the skeletonized NMJ that connect three branches.

Voxels

The three-dimensional building blocks (“pixels”) in the 3D skeletonized NMJ.

Endpoint voxels

The number of voxels with only one neighbor voxel.

Slab voxels

The number of voxels with two neighbor voxels.

Junction voxels

The number of voxels with more than two neighbor voxels.

Average branch length

The mean branch length of all branches in the skeletonized NMJ.

Maximum branch

The length of the longest branch in the skeletonized NMJ.

length

Longest shortest path

The shortest path distances between all possible endpoint pairs in the skeletonized NMJ
are determined. The longest of these shortest path distances is then identified.

Area to Volume Ratio

The surface area to volume ratio of the NMJ.
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2.7

Determination of Nuclear Distribution

To analyze nuclei morphology at the NMJ, we processed confocal images with Image J
software. Confocal images in the ‘Maximum Intensity Projection’ format were utilized
for length and width measurements of the nuclei. First the area around the NMJ was
delineated to help identify nuclei associated with the synapse for analysis. This was done
with the help of the MorphoLibJ plug-in (Legland et al, 2016). ‘Morphological filters’
are applied to images of the AChRs using a disk to set a 38-pixel dilation for all images
to capture associated nuclei, any nuclei that has more than 50% of its area within this
region is counted. This is further confirmed by rotating the image in 3D. Nuclei that do
not meet this criterion and that fall outside the dilated region are excluded from the
analysis. After the background is adjusted on the image, the wand tool is used to mark out
the boundaries of the dilated region (Figure 15). This region is saved using the ROI
manager, and later applied to images of the nuclei to obtain the relevant nucleus for
analysis. The line drawing tool was used to mark out the length and width of the nucleus
which were perpendicular to each other and drawn from the farthest points of the nuclei
in each direction. The longest distance was considered the length and the shortest the
width, the ellipticity value is obtained by dividing the width by the length.
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Figure 15 Illustration of analysis on sub-synaptic nuclei
A 10µm radius is marked on confocal images of the NMJ to include relevant subsynaptic nuclei for the analysis. The length and width of all nuclei that fall within this
radius are determined and the ellipticity calculated.
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CHAPTER 3:BEHAVIORAL CHARACTERIZATION OF CMT2O
MOUSE MODELS
3.1

Introduction

A lot of what is known about dynein function has come from studies in different systems,
such as yeast, fungi, fruit flies and mice (Wickstead and Gull, 2007, Moore et al, 2009,
Egan et al, 2012). Knockdown studies in mice provided strong evidence showing that
dynein is imperative in supporting life (Harada et al, 1998). The use of animal models of
disease however requires first, the investigation and identification of phenotypes related
to the disease. The dynein mouse models Loa, Cra, and Swl have been well characterized
with motor and sensory abnormalities (Schiavo et al, 2013).

The first characterized human mutation in the dynein heavy chain was found to cause
CMT disease, specifically type 2O. (Weedon et al, 2011). We therefore made a knock-in
mouse with the corresponding H304R mutation that causes CMT2O to study the disease
and obtain further insight into how dynein function is altered. CMT2O patients usually
develop muscle weakness, gait problems and delayed milestones (Weedon et al,2011).
Based on the presentation of the disease in humans, a good mouse model should have
similar motor phenotypes. To find out if our CMT2O mouse models had a phenotype
reminiscent of CMT disease, we conducted a longitudinal assessment of the locomotor
skills of wild-type and mutant mice bearing the H304R mutation. We employed 3 assays
namely; the tail suspension assay, grip strength measurements and motor coordination
assessment. These assays have been widely used to determine neuromuscular
impairments in various animal models of disease (Brooks and Dunnett, 2009). Dynein
mouse models (loa, cra, swl) and some CMT2 mouse models (CMT2D, CMT2E) have
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been assessed for their locomotor properties via the tail suspension and motor
coordination on the rotarod (Rogers et al, 2001, Dequen et al, 2010, Shen et al, 2011).
The choice of these motor behavioral assays gives us a basis for comparison of results
with studies involving other CMT2 and dynein mouse models.

3.2
3.2.1

Results

Investigation of defects in the heterozygous mouse

We generated a heterozygous knock-in mouse line that carries the corresponding H304R
mutation in the mouse cytoplasmic dynein gene. We characterized potential loco-motor
phenotypes by examining both male and female littermate wild-type and H304R/+ mice
in a 12-month longitudinal study. Over the time points analyzed, H304R/+ mice had no
obvious physical or cage behavioral phenotypes that could be distinguished by eye from
littermate wild-type animals. We tracked the general health of those animals and saw no
obvious health differences in the animals outside of a modest weight gain in 3-month old
female H304R/+ mice that disappeared as the mice aged

3.2.1.1 General observations and cage behavior
All mice regardless of genotype were bred using the same scheme and housed under
standard conditions with unlimited access to food, water and cage enrichment. For
purposes of our behavioral study, male and female mice were separated into different
cages after weaning. All mice were periodically observed to assess their general wellbeing or to pick out signs of ill-health. Some of the signs we looked out for were; the
level of activity, condition of the fur, skin and eyes, locomotion, posture and examination
of cage litter for signs of fecal and urine elimination. This exercise is particularly critical
for a novel mutation, because we do not know how the introduction of the transgene
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affects the behavior of the litter. We recorded all health concerns encountered and the
response to treatment as well. After comparing the genotypes of animals with health
concerns, we ruled out the contribution of the H304R dynein heavy chain mutation. We
tracked the weights of the mice and found no significant genotype –specific effect on
weight change over the duration of the study.

3.2.1.2 Picking out the right tools to determine phenotype
We started out by analyzing behavioral phenotypes making use of some well-known
assays, namely; wire mesh, the hanging rod both of which test for locomotion and
balance (Figure 16). For gait analysis we painted the feet of the animals; utilizing two
different colors to differentiate front paws from hind paws (Crawley,2008). Although
these assays were suitable for other phenotypes, with the exception of the tail suspension
assay, we obtained very little reproducible results with our mice. We resorted to the use
testing methods that required minimal tester involvement in our bid to find out whether
the H304R mutation had any phenotype based on published work on dynein and CMT2
mouse models (Rogers et al, 2001 Bogdanik et al,2013, Zhang et al,2014). We therefore
settled on the rotarod and grip strength meter which came with software packages to
automatically record data for analysis. The use of these equipment resulted in more
efficient work as it eliminated a lot of optimization and troubleshooting time. Testers
were blind to the genotype of the mice, and they carried out initial trials with the mice
before actual performance measurements. The rotarod required testing out different
parameters to determine the most suitable testing condition.
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A

B

Figure 16 Mouse footprints assay
A sample of the output from the footprint assay with fore and hind paws distinguished by
different colors and showing 2 patterns of footsteps. A) Regular footprints from a mouse
that took normal steps. B). Irregular pattern of footprints obtained from a mouse that
could be jogging or running.
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3.2.1.3 H304R/+ mutant mice show an altered tail suspension reflex
Wild-type mice generally display a characteristic tail suspension reflex of splayed hind
limbs held away from their body when suspended by their tails. Several studies of Loa/+,
Cra/+ and Swl/+ mice pointed out that those mice display an atypical phenotype of
clenching their hind limbs when suspended by their tails. We performed a similar tail
suspension assay at successive 3-month time points and found that the majority of male
and female wild-type and H304R/+ mice displayed the normal splayed tail suspension
reflex phenotype at each time. However, both male and female H304R/+ mice showed a
significant increase (p <0.05) in atypical tail suspension responses relative to wild-type at
9 and 12 months (Figure 17A). These data suggest that the H304R/+mice have a hind
limb defect but that the defect is less pronounced than the phenotypes in Loa/+, Cra/+,
and Swl/+ mice as only a subset of H304R/+ mice display the atypical response.

3.2.1.4 H304R/+ mutant mice have reduced muscular strength
We next analyzed the limb muscular strength in our mice using a standard grip strength
assay. Male H304R/+ mice exhibited significant weakness in all limb grip strength
relative to wild-type male mice at all ages examined. To further tease apart the
contribution of front and hind limbs to this phenotype, we examined the strength of the
front limbs solely. We found that there was a significant, progressive weakness in front
limb grip strength of male H304R/+ mice relative to wild-type mice that occurred in the
later 9 and 12-month time points (p< 0.05) (Figure 17B). These data suggest that the
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mice have reduced function in the hind limbs at an early age, and that front limb
weakness progresses as the mice age.
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A

B
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C

Figure 17 Motor performance test results
Behavioral phenotypes of H304R/+ mice. (A)The atypical tail suspension reflex was
scored and counted for each test mouse per 3-month long time intervals and the scores
were statistically compared between the wild-type and H304R/+ mice groups using
Fisher’s Exact Test (two-tailed distribution, p<0.05). (B)The grip strength was measured
in the all limbs of the male and female mice, and in the front limbs of the male and
female mice. The data was statistically compared between wild-type (filled circles) and
the H304R/+ (empty circles) mice groups using the t-test (two-tailed distribution, *=
p<0.05). (C)The rotarod performance was measured for both the male and female mice.
Grip and rotarod readings from each test mouse was then averaged per 3-month long time
intervals respectively. The data was statistically compared between wild-type (filled
circles) and the H304R/+ (empty circles) mice groups using the t-test (two-tailed
distribution, *= p<0.05).
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When we examined female mice, we found subtle defects in the combined grip strength
at 6 and 9 months of age for H304R/+ females, but no defect in front limb grip strength at
any age. The grip strength data is consistent with our tail suspension data, showing that
there is a general trend of reduced neuromuscular function in H304R/+ animals as they
age.

3.2.1.5 H304R/+ mutant mice have motor coordination defects
The rotarod test is a performance-based test for the evaluation of muscular endurance,
motor coordination and balance in mice. We utilized an accelerating profile where the
mice were tested for their ability to adjust to increasing revolutions during a ramp time
followed by a consistent speed for the remainder of the assay. When we examined the
ability of wild-type and H304R/+ littermates to perform this assay, we found that
individual animals of a particular genotype could exhibit a wide range of abilities.
However, as a group, H304R/+ males had reduced rotarod performance at 3, 6, and 9month time points (Figure 17C). Female H304R/+ mice only displayed a significant
difference in rotarod performance at the earliest time point examined. This difference
disappeared as the female mice aged. Loa/+ mice had been previously characterized with
the rotarod test and showed similar defects.
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3.2.2

Characterization of the homozygous mouse model

The H306R mutation originally discovered in the cytoplasmic dynein heavy chain in
humans occurs as an autosomal dominant heterozygous genetic defect (Weedon et
al,2011). Heterozygous mutations in loa, cra, swl mice have provided some clues about
how a mutation in dynein can lead to neurological dysfunction. Homozygous mice with
the loa, cra, swl mutation result in early lethality and therefore a study of the progression
of the disease and the effects on the motor in these disease models hasn’t been possible.
A homozygous dynein mouse model that is able survive long enough for a longitudinal
assessment will fill that gap. Our H304R/R homozygous mouse fortunately addresses
that, with homozygous animals able to survive beyond the first year of life. Of particular
interest was the discovery of homozygous dynein in an individual from a genetic screen
involving 30 subjects (Scoto et al,2015). This individual with the homozygous mutation
had arthrogryposis from birth, cognitive impairment and ADHD (attention deficit
hyperactive disorder). These features were more severe than what the heterozygous
parents had. One parent had muscular weakness and denervation in the lower limbs
whereas the other showed no obvious symptoms.

Generally, the homozygous mice had deficits at all time points looked at. Furthermore,
the gender differences that were a feature of the heterozygous mice, (ie. females having a
weaker phenotype) appear to have diminished in the homozygous mice. A study in
Germany looked at gender differences among CMT patients and gender was found to
play a role in the incidence of muscle force in the lower limbs, with men being affected
more than women (Wozniak et al, 2015). This finding agrees with the pattern observed in
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our behavioral assays in heterozygotes, where female mice generally had a weaker
phenotype compared to males.

3.2.2.1 H304R/R mice survive after birth
After obtaining the approval to breed homozygous mutants from two heterozygous
parents, we were initially curious in finding out whether the homozygous mice will
survive after birth and if so, how long their life span will be. The homozygous mutation is
lethal in other dynein mutants, with mice surviving only a few days after birth. H304R/R
homozygous mice survive up to 2 years after birth and as such can undergo a longitudinal
assessment of phenotypes similar to what was done in heterozygous mice (Sabblah et al,
2018). H304R/R homozygous mice can be differentiated from wild-type and even
heterozygotes by the 30th day after birth. Some of the mice are often smaller and develop
a characteristic high steppage gait.

3.2.2.2 H304R/R homozygous mice have severe neurological impairments
We carried out motor performance assays, namely tail suspension, muscle strength and
motor coordination in homozygous mice to characterize their phenotype. We tested both
male and female mice at 5 timepoints altogether:1 month, 3 months, 6 months, 9 months
and 12 months. We were anticipating a harsher effect of the mutation on neuromuscular
performance, however, we didn’t know what to expect in terms of progression and how
the general activity of the mice will be affected and whether gender differences will be
seen, as was the case with heterozygotes.
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Our neurological assessment of mice based on hind limb clasping in the tail suspension
assay confirmed our expectations as homozygous mice presented a more robust
phenotype (Figure 18). About 60% of homozygous animals clenched their hind limbs
and often writhed in an attempt to assume a more comfortable posture (Figure 19A). This
peculiar behavior often made the homozygous distinguishable from the other genotypes.

3.2.2.3 Homozygous mice show a pronounced motor phenotype
Atrophy of the muscle, weakness and gait problems are well-documented in CMT2 and
peripheral neuropathies in general. Other dynein mouse models also presented with
muscular issues as well, therefore it was only a question of how severely the H304R/R
homozygous model will be affected. We first evaluated muscle strength in all limbs of
the mice on the grip meter. Lower values were consistently recorded for homozygous
mice throughout the study. In female homozygous mice the deficiency in the muscle was
seen earlier at 3-months whereas in heterozygotes differences occurred at 6 months
(Figure 25). To tease out the contribution of each set of limbs to the phenotype, we took
grip strength readings in the fore limbs. We found reduced muscular strength in forelimbs
of mice meaning that in the homozygous mice both fore and hind limbs are targets of the
peripheral neuropathy. Both males and females suffered in the fore and hind limbs.

Motor coordination discrepancies were also observed consistently at all time points in
both male and female mice. Homozygous mice on the average, fell of the rotarod before
the 60 second ramp time set on the instrument (Figure 11). Although the motor
phenotypes didn’t progressively worsen in homozygous mice over time, the performance
of mice on the assays reveals the severity of the homozygous mutation.
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Figure 18 Hind limb posture in mice on the tail suspension assay
Scores are given based on widely apart animal hold their hind limbs apart. Wild-type
mice are typically awarded a score of 3 the highest score, majority of the heterozygous
mice score 2 displaying mostly 2 forms of partial limb clasping. Homozygotes largely
obtain a score of 1 as they are unable to keep their feet apart and have them clutched
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Figure 19 Phenotypic assessment of homozygous mice
Hind limb posture assessed in mice (A, B). Muscle strength in all limbs was measured
with the help of a grip meter (C, D). Fore limb strength alone was also measured (E, F).
Motor coordination based on the latency of the animal to fall was determined on the
rotarod (G, H)
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3.3

Discussion

3.3.1 Assessment of H304R Phenotype
To gain understanding of the onset and progression of axonal CMT as well as the role of
cytoplasmic dynein in cellular neuropathy, we have generated and initially characterized
a knock-in mouse carrying the H304R mutation in the cytoplasmic dynein heavy chain.
This mutation corresponds exactly to the human H306R DHC mutation that results in
CMT2O (Weedon et al,2011). We examined both male and female H304R/+ mouse
cohorts in a 12-month longitudinal assessment study to determine if the mutant DHC
allele causes dominant locomotor deficits similar to those exhibited by individuals with
CMT2; we also assessed whether H304R/+ male mice have neuromuscular pathologies.

H304R/+ male mice exhibit phenotypes that would be expected for a mouse model of
CMT disease. The mice displayed muscle weakness, loss of motor coordination and
atypical tail suspension reflexes compared to littermate controls. In addition, although
our assay could not distinguish hind limb muscle strength directly, the progression of
limb weakness from early onset “all limb” only to significant weakness in the forelimbs
specifically at the later time points strongly suggests that the mouse disease pathology is
following the progression of symptoms in humans from difficulty walking to progressive
inability to use hands effectively.

Interestingly, we found differences in severity of phenotypes based on the sex of the
animal, with female animals having weaker phenotypes overall compared to male
counterparts when measuring grip strength and motor coordination but similar atypical
tail suspension reflexes. We believe that our female H304R/+ mice exhibit milder CMT
characteristics that will require more sensitive locomotor assays to distinguish. The initial
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study of human CMT Type 2O characterized 8 males and 5 females in detail, with no
obvious differences between the sexes being noted (Weedon et al,2011). It is possible that
our observed difference in expressivity of H304R/+ between males and females is due to
specific sexual differences in the characteristics of mice; it will be extremely interesting
to determine if the variation in expressivity occurs at the cellular level. Especially when
sex differences have been observed among CMT patients in a study looking into the
severity of the disease (Wozniack et al, 2015).

3.3.2

Phenotypic features of the H304R/R homozygous mouse

The phenotypes observed in our CMT2O homozygous mice were expectedly more severe
than heterozygous animals, but there is also a difference in the way the homozygotes are
affected. Homozygous mice are distinguishable from heterozygotes in appearance, they
generally weigh less and are smaller and develop a high steppage gait at about 14 days
after birth. Our behavior data shows that the predominant motor phenotype due to the
H304R mutation in the dynein heavy chain is more pronounced in the homozygotes as it
develops earlier than in the heterozygotes in some cases. Significantly the sex differences
in the phenotype were eliminated as the both males and females recorded comparable
behavioral deficits. For instance, there were no deficits recorded in the heterozygous
female fore limb strength, however the homozygotes displayed fore limb weakness at all
the time points looked at compared to male mice (Figure 19). Although the reason for the
minimized effect of the CMT-related phenotype is not known in females, it is obvious the
homozygous mutant protein and therefore dynein is affected strongly enough to produce
a robust phenotype in males. Another factor that is worth noting is in terms of the
progression of the disease is that the ability of the animals to recover is lost with the
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homozygous mutation. Motor coordination is restored in male mice by the 12th month
and in female mice by the 6th month in heterozygotes, in the homozygous however, all
time points are affected. Simultaneously there appears to be the early development of a
motor phenotype in the homozygous animals, this is also corroborated in the data on
NMJ analysis.
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CHAPTER 4:HISTOLOGICAL ANALYSIS OF MUSCLE
FUNCTION
4.1

Introduction

Cytoplasmic dynein has specialized roles in specific cell types in as much as there are
general functions in many cells. This is perhaps one of the factors underlying the wide
range of symptoms observed in living organisms when there is mutation in the
cytoplasmic dynein gene. A typical investigation into a dynein therefore should include
the isolation and investigation of different subcellular components for further analysis.
Different studies have shown how dynein mutations can affect some cellular targets and
not others (Dupuis et al, 2009, Braunstein et al, 2010, Eschbach et al, 2011). The loa, cra
and swl dynein mutations have been examined at the tissue level for neuromuscular
abnormalities. The neuromuscular junction was found to be affected by perturbations in
dynein function in the cra heterozygous mice (Courchesne et al, 2011). The link between
dynein and neuromuscular junction dysmorphology could be due to dynein activity in
motor nerves (LaMonte et al, 2002, Levy and Holzbaur, 2006).

The results of our initial loco-motor studies, altered behavior in tail suspension, grip
strength, and rotarod assays, suggested to us that there might be a physical defect in the
neuromuscular system in the mutant H304R/+ mice. To examine this possibility directly,
we characterized the sarcomere and neuromuscular organization of the gastrocnemius
lower limb muscle from male wild-type and mutant mice. We chose to examine
specifically male mice, as they exhibited more significant motor behavior skills defects
than female mice. Fixed gastrocnemius muscle tissue slices were labeled with antibodies
for key components of those structures and imaged using standard confocal microscopy.
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Our survey of 9 and 12-month tissue showed no defect in the number or overall
organization of sarcomeres between wild-type and H304R/+ mutant mice

4.2
4.2.1

Results

Investigation of Defects in the heterozygous mouse

We tested the possibility of the defects in mice arising from an improperly assembled
motor protein by comparing the levels of dynein in the brains of wild-type to mutant
(H304R/+) mice. Quantification done on the immunoblot showed no difference in the
levels of the intermediate chain of dynein (Figure 18). We were unable to specifically
examine dynein heavy chain protein levels in the brain samples due to incomplete
transfer of the approximately 4700 amino acid protein from the gel to the membrane.

The results of our initial loco-motor studies, altered behavior in tail suspension, grip
strength, and rotarod assays, suggested to us that there might be a physical defect in the
neuromuscular system in the mutant H304R/+ mice. To examine this possibility directly,
we characterized the sarcomere and neuromuscular organization of the gastrocnemius
lower limb muscle from male wild-type and mutant mice. We chose to examine
specifically male mice, as they exhibited more significant motor behavior skills defects
than female mice. Fixed gastrocnemius muscle tissue slices were labeled with antibodies
for key components of those structures and imaged using standard confocal microscopy.
We examined sarcomere organization by staining the Z-line with alpha-actinin (Figure
19). We saw no qualitative difference between images of wild-type and H304R/+ mutant
mice. We also measured the mean sarcomere distance in the muscles and saw no
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significant difference (p= 0.08) between those of wild-type (2.22 µm sarcomere length
from 11 muscle fibers and 689 individual sarcomeres) and H304R/+ (2.20 µm sarcomere
length from 11 muscle fibers and 702 individual sarcomeres).

4.2.1.1 Determining complexity in the NMJ architecture
Complexity is a classical feature of the mature neuromuscular junction and resulting
changes in architecture could also be valuable in predicting the involvement of some kind
of neuromuscular pathology. It is therefore important to be able to capture and quantify
the various changes that could occur in the event of an underlying disease in the course of
development. NMJ complexity in simple terms is descried as a ‘pretzel-like’ structure
after a series of transformations have occurred from the initial ‘cookie’ structure or
plaque early in development. In situations where the changes are subtle, it is important to
have analytical tools that are both sensitive enough and at the same time reproducible.
Complexity has been previously defined based on different ways of studying
neuromuscular junctions (Courchesne et al, 2011, Sleigh et al,2014). We used plug-ins
from ImageJ software to determine NMJ complexity based on 10 parameters (Table1).
The advantage is that minor changes over time can be noticed as was the case for early
time points in our longitudinal study of the H304R mutation in the dynein heavy chain.
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Figure 20 Dynein expression in brain of mice
Protein levels of the dynein intermediate chain from brain tissue high speed supernatant
of both wild-type and heterozygous mice. Statistical analysis using the student’s t-test,
two-tailed distribution, showed no significant difference in protein expression (p=0.23)
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A

B

Figure 21 Sarcomere organization in heterozygous mice
A) Gastrocnemius muscles were stained with α-actinin to show the Z-line (in green) in
the sarcomeres of wild type and mutant H304R/+ mice. B) No differences were observed
in the length of the sarcomere in wild type and H304R/+ muscle tissue

81

Figure 22 General morphology of NMJs in mice
AChRs from wild-type and heterozygous (H304R/+) mice at 9 and 12 months were
stained to assess the morphology of the NMJ. Wild-type muscles had more of the typical
complex morphology compared to mutant heterozygous mice.
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4.2.1.2 Neuromuscular junction dysmorphology
We labeled 9 and 12-month tissue slices with fluorescent alpha-bungarotoxin to examine
the NMJs of wild-type and H304R/+ mice. NMJs from wild-type mice displayed the classic
pretzel shaped morphology with a highly branched complex appearance (Sanes and
Lichtman, 2001). However, NMJs from H304R/+ animals presented a mixture of NMJ
morphologies ranging from the classic morphology to those with obvious defects in size,
branches, and complexity.

To more thoroughly characterize the NMJ defect, gastrocnemius tissue samples were
analyzed from both wild-type and mutant H304R/+ mice from 1, 3, 6, 9, and 12-month old
male animals. Qualitatively, we saw abnormal NMJ complexity/morphology in 1-month
H304R/+ tissue and no discernable phenotype in 3-month H304R/+ tissue. This was
followed by an increasing percentage of NMJs with more obvious defective morphologies
in the 6, 9, and 12-month time-points. However, not all NMJs were abnormal in the
H304R/+ mice: there was a range of NMJ morphologies present at all time points. We
found that an individual mouse could display a mixture of normal and abnormal NMJ
morphologies and that there was a range of abnormalities present in the NMJs
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Figure 23 Altered neuromuscular junction morphology
Confocal images of representative NMJs stained with neurofilament (red) and alphabungarotoxin (green) at different time points. A: 1 month, B: 3 months, C: 6 months, D: 9
months, E: 12 months. Graphs show twelve parameters that were examined for the NMJ
architecture in wild-type and H304R/+ animals, displayed as the H304R/+ percentage of
the wild type value, grey bars represent H304R/+, black dotted line is wild-type.
Statistically significant differences between wild type and H304R/+ values are indicated
by * (two-tailed distribution, p<0.05). Scale bar =20µm
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To quantitatively characterize the defects in NMJ morphology we processed image stacks
of AChR fluorescence as described in Materials and Methods. Our analysis identified
several interesting features that occur as the mice reach and pass through adulthood. At
one month of age, H304R/+ NMJs have statistically significant defects in six of the
parameters examined (Figure 21A). Notably, the one-month H304R/+ NMJs have fewer
branches as seen by the branch, junction voxel, and triple point parameters. Furthermore,
the branches present are longer than those in wild-type animals.

Finally, there is a

reduction in the surface area to volume ratio of the entire NMJ. These characteristics can
be seen in Figure 21A as these representative H304R/+ NMJs show fewer longer branches
present. At three months of age the overall morphology of H304R/+ and wild-type NMJs
were indistinguishable and the quantitative analysis was unable to identify any parameters
with statistically significant differences.

At six months of age we observed a small subset of H304R/+ NMJs that appeared less
complex than the typical wild-type NMJ. However, these were only a fraction of the
overall NMJs and the surface area/volume ratio was only parameter with a statistically
significant difference between genotypes (Figure 21C). At the 9-month time point, there
were a sizeable percentage of H304R/+ NMJs with obvious morphological defects (Figure
21D). Our analysis showed that there was a reduction in most of the quantitative
parameters we measured, and that reduction was statistically significant for four of the
parameters in H304R/+ mice compared to wild-type littermate control mice (Table 1).We
found the decrease in the percentage of NMJs that were innervated to be especially
interesting as it may indicate that some form of degeneration may have occurred in these
older NMJs.
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The NMJs of 12-month old H304R/+ mice had severe defects from both qualitative and
quantitative assessments. Many of the H304R/+ NMJs had a wider junction diameter with
a notable reduction in the number of branches present (Figure 21E). Our quantitative
analysis of H304R/+ NMJs identified ten parameters with statistically significant decreases
relative to age matched wild-type NMJs (Table 1). These differences are indicative of the
gross abnormalities present in many of the H304R/+ NMJs. The percentage of NMJs that
were innervated correctly was dramatically reduced in the H304R/+ NMJs at 12 months
similar to the 9-month time point.

4.2.2

Analysis of Defects in the CMT2O Homozygous Mouse Model

To delve deeper into how a point mutation (H304R) in the dynein heavy chain leads to
dynein dysfunction and result in CMT disease-related phenotypes in our mouse model,
we bred two heterozygotes to generate homozygous mice with the mutation in both
dynein heavy chain genes. We assessed the phenotype of the homozygous mice through
our behavioral assays and discovered stronger phenotypes than previously noticed in
heterozygous mice and therefore a wider difference when compared to wild-type versus
heterozygotes compared to wild-type. We were interested in whether neuromuscular
abnormalities in the tissue of homozygous mice would similarly be worse than
heterozygotes. Firstly, we examined sarcomere organization in 12-month-old male
homozygous mice and compared the results to both age-matched wild-type and
heterozygous mice. We chose 12-month old animals because they represent the stage at
which mice show with the most drastic effect from the H304R dynein mutation.
Sarcomere measurements were taken based on alpha-actinin staining of Z-lines in muscle
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fibers of gastrocnemius muscles. There were no obvious genotype-specific differences
judging from the arrangement of Z-lines in muscle fibers from confocal images (Figure
24A).

However, we noticed a slight reduction in sarcomere lengths in homozygous mice with a
mean sarcomere length of 2.11µm (Figure 24B). This value represents a 5% decrease
compared to wild-type (2.22µm) and a 4% decrease compared to heterozygote mean
sarcomere length (2.20µm). This difference in sarcomere length between wild-type mice
and mutants was statistically significant (p<0.05). More experiments are needed to
determine the reason for the change in sarcomere length, and if it is a direct or indirect
result of dynein dysfunction. Sarcomere organization in the fruit fly, was found to occur
after nuclear placement in the muscle fibers (Auld and Folker, 2016). Should this be true
in mice as well, it could partly explain why sarcomere lengths in homozygous mice may
be slightly altered. This is because our preliminary assessment of myonuclear positioning
of subsynaptic nuclei suggests some discrepancies in homozygous mice at the 12-month
time point (Figure 29).
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Figure 24 Sarcomere organization in homozygous mice
a) Representative images of sarcomeres in gastrocnemius muscles of 12-month-old mice
for each genotype b) graph showing mean sarcomere lengths in muscle fibers for each
genotype. The mean values were obtained from 682 wild-type,702 H304R/+ and 744
H304R/R individual sarcomeres
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Figure 25 Comparison of NMJ morphology across genotypes
Representative images of AChRs for each genotype based on alpha bungarotoxin staining
at 12 months. Homozygous NMJs were clearly distinguishable from wild-type and even
heterozygotes by being less branched and less connected branches. They also displayed
fragmentation and had more regions of low fluorescent intensity. Heterozygous NMJs
compared to wild-type were generally less complex.
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4.2.2.1 H304R/R homozygous mice display more defects in motor endplate architecture
Heterozygous mice showed aberrations in the organization of the NMJ as well as
innervation defects at 9 and 12 months compared to wild-type mice. We compared the
general morphology of NMJs from gastrocnemius muscles of homozygous mice to wild
type and heterozygotes and we saw more severe abnormalities (Figure 23). The NMJs
were generally disconnected and unlike the heterozygote muscles, there were more
fragmented NMJs. Homozygous mice displayed very low NMJ complexity and in some
instances had regions of low receptor density. They appeared smaller in size and quite a
number of them had no nerves at all. We proceeded with a longitudinal assessment of
NMJ innervation and architecture at 1 month. 3 months, 6 months, 9 months and 12
months. In terms of innervation, H304R/R mice were notably different from H304R/+
mice by showing consistent deficits at all time points from 1 month to 12 months. The
number of NMJs that were innervated was higher at 9 months and 12 months compared
to wild type but also lower than that of heterozygous mice.
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Figure 26 Abnormal NMJ architecture in gastrocnemius muscles of H304R/R mice
Confocal images of representative NMJs stained with neurofilament (red) and alphabungarotoxin (green) at different time points. A: 1 month, B: 3 months, C: 6 months, D: 9
months, E: 12 months. Graphs show twelve parameters that were examined for the NMJ
architecture in wild-type and H304R/+ and H304R/R animals as the percentage of the
wild type value. Grey bars represent H304R/+, striped bars are H304R/R, red dotted line
is wild-type. Statistically significant differences between wild type and H304R/+ shown
by * and differences between wild type and H304R/R values are indicated by * (twotailed distribution, p<0.05). Scale bar =20µm
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Table 2 Morphological assessment of wild-type and mutant NMJs

The number of AChRs analyzed (n), number of animals per genotype (N) and mean values (± standard
deviation) of different parameters assessing NMJ complexity. Innervation is shown as the percent of examined
NMJs with nerves that occupy more than half of the receptor volume. SA / VOL: surface area to volume ratio.
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The dysmorphology of NMJ architecture is seen more strongly at 1 month than in
H304R/+ with differences observed in more of the parameters. Whereas there were no
abnormalities observed in H304R/+ mice at 3 months, homozygous mice continue to
show differences in complexity when compared to wild-type and heterozygotes (Figure
26B). However, at 6 months the effect of the H304R mutation on NMJ complexity seems
to be slightly reduced compared to earlier time points. There were significant differences
in 6 of the complexity parameters compared to 9 parameters at 3 months. Previously in
H304R/+ mice only surface area to volume ratio was different from normal mice. At 9
months, the NMJ abnormalities in the homozygous mice are more pronounced, an
obvious deterioration from the 6-month time point. The defects in NMJ organization are
most severe at 12 months compared with wild type, with lower values than heterozygous
(Figure 26E).

4.2.2.2 H304R/R homozygous mice show abnormalities in innervation
Innervation defects were consistently recorded in homozygous mice from 1 month to 6
months, worsening by 9 months and 12 months. Our analysis pointed to denervation in a
number of homozygous NMJs with negative staining for neurofilament. Even though less
NMJs are innervated in homozygous mice, we focused on the NMJs with nerves present
and asked if synaptic activity was normal in these nerves. To ascertain the functionality
of the neuromuscular synapse beyond the mere presence of neurofilament positive
staining, we assessed synaptophysin occupancy at the NMJ as a measure of a functioning
synapse.
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Figure 27 Synaptic dysfunction in H304R/R homozygous mice
Representative images of synaptophysin density (red) at each time point in pre-synaptic
nerves (blue) at the neuromuscular junction of mice. The post-synaptic apparatus is
stained with alpha–bungarotoxin (green).

99

Synaptophysin is a membrane protein of synaptic vesicles which is widely used as a
marker for synaptic vesicles (Valtorta et al, 2004). The synaptophysin occupancy is
obtained from the area of synaptophysin staining divided over the area of AChR staining.
In heterozygotes, there were no statistically significant differences in synaptic vesicle
density at early time points, significant differences were observed beginning from 6
months till 12 months (Figure 25). Although a significant reduction in the number of
innervated NMJs is not observed in heterozygotes till 9 months, a reduction in synaptic
vesicle density occurs earlier at 6 months. The density of synaptic vesicles does not
drastically reduce over time but remains almost constant from 6 to 12 months. In
H304R/R mice, synaptic vesicle density was consistently lower than wild-type and
H304R/+ mice, however not all these differences were statistically significant.
Differences between wild –type and homozygous were significant at all time points
examined.
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Figure 28 Synaptic vesicle density at the presynaptic apparatus
Gastrocnemius muscle sections were stained for synaptophysin and the AChR and
images acquired via confocal microscopy. Heterozygous mice display deficits in
synaptophysin density beginning from 6 months, whereas homozygotes show defects
from the first month up to 12 months. Synaptic vesicle density is expressed as a
percentage of AChR area and was computed as follows: (synaptophysin area/ AChR
area) x100. Statistical analysis was carried out using Graph pad and by employing the
one-way-ANOVA, p<0.05
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4.2.2.3 Homozygous mice show differences in sub-synaptic nuclei distribution
Molecular motors are required for the positioning of nuclei in different cell types; and
mispositioning of nuclei is a hallmark of some muscular disorders. We noticed
differences in the appearance of nuclei associated with the NMJs between wild-type and
heterozygous mice. These nuclei looked different in terms of their morphology, and
arrangement and at times, the number of nuclei also varied between genotypes. After we
generated homozygous mice with the dynein H304R mutation we continued to notice
these differences. The nuclei at the neuromuscular junction or sub-synaptic nuclei play
some distinct roles that sets them apart from the other nuclei in the muscle (Moscoso et
al, 1995), it is therefore possible they would be targeted as the H304R mutation leads to
disruptions in NMJ architecture. We proceeded to investigate the differences observed in
sub-synaptic nuclear arrangement at the NMJ by focusing on the morphology of the
nuclei and the number present at the synapse. We chose to look first at mice that were 12
months of age, since we saw a more pronounced neuromuscular dysfunction at this time
point. We determined the ellipticity of the nuclei to differentiate more oval elongated
nuclei from more rounded nuclei. The neuromuscular synapse is also infiltrated by nuclei
from the glial cells which help stabilize the entire apparatus also. Our initial study of
nuclear morphology and distribution in 12-month-old mice revealed the abundance of
more elongated nuclei in the muscles of homozygous mice compared to wild type and
even heterozygotes. The heterozygotes seemed to have more mid-point ellipticity scores
as seen also in the histogram that quantifies the distribution of these nuclei (Figure 29).
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Further studies into establishing the identity of nuclei either as myonuclei or glial cell
nuclei as well as results from other timepoints are ongoing.

104

A

B

C
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Figure 29 Distribution of nuclei at the neuromuscular junction
A) Schematic depicting nuclear morphology at the NMJ from three genotypes (wild-type,
heterozygous and homozygous) based on confocal images from12 month old mice. The
area enclosed by the NMJ is marked in yellow as well as the nuclei analyzed. The
ellipticity scores are shown in boxes and have been color-coded to match the respective
nuclei. Ellipticity is calculated by dividing the width by the length of the nuclei. B)
Histogram showing nuclear ellipticity in each genotype as a percent of all nuclei.
(Number of nuclei analyzed: wild-type=39, H304R/+ =32, H304R/+=34) C) Distribution
of nuclear ellipticity at the NMJ compared across genotypes. Black bars are wild-type,
grey bars heterozygotes and dark blue bars homozygotes
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4.3

Discussion

4.3.1.1 Changes in NMJ architecture in H304R heterozygous mice
Based on the motor behavior phenotypes we observed, we decided to examine NMJ
morphologies in male H304R/+ mice and saw significant differences in NMJ
morphologies over time (Table 2). We found that NMJs appeared under-developed at
one-month of age, with fewer branches, and with those branches having significantly
longer lengths. However, this phenotype disappeared at 3 months, as the NMJs were
indistinguishable from control animals at that age. At later time points the NMJs lost
complexity, and many times appeared to have a larger synapse diameter. One of the most
interesting features of the H304R/+ phenotype was the apparent recovery of NMJ
morphology in young adult mice followed by degeneration as the mice aged. The defects
seen at the earliest time point seem to represent a problem in development of the NMJs,
as less complexity was present. In contrast, the defects seen in the later time points
suggests that there may be a separate mechanism in the older animals that is causing
possible retraction or degeneration at the NMJ during aging. Future work will be needed
to test those possibilities.

4.3.1.2 Altered neuromuscular junction morphology in H304R/R animals
Although CMT disease occurs in humans as an autosomal dominant heterozygous
mutation, there are some benefits in generating homozygous individuals. From a
biochemical standpoint isolating components of the mutant dynein complex for further
analysis is more feasible in a homozygous animal than a heterozygous. This is because
the population of wild-type or normal dynein that would be present in every isolated
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fraction is eliminated. Another reason why a homozygous mouse model is exciting is the
possibility of studying understanding the function or dysfunction of dynein more clearly
as the protein function is more severely affected compared to the heterozygous model.
loa/loa homozygous mice die within a day of birth, however studies on the embryos have
shed more light on the essential functions of dynein in neurons during development
(Hafezparast et al, 2003, Ori-McKenney and Vallee, 2011).

Homozygous mice displayed dysmorphology at the NMJ at all time points analyzed, a
more careful scrutiny of the results point to a lessening of the effects on the NMJ at 6
months until it increases again from 9 months till the animals are 12 months. Unlike
heterozygous mice where there is no difference in NMJ complexity at 3 months, the
H304R/R mice have less severe abnormalities at 6 months. It is possible that the
heterozygotes are able to overcome some of the relatively milder developmental
problems by 3 months, but the homozygotes are never able to fully do so since they have
more severe effects. Even at 6 months when the where there is a diminished effect
compared to other time points, abnormalities at the NMJ still remain when compared
with wild type mice. The H304R/R homozygous mouse model is not the first attempt at
generating a homozygous dynein mouse model, but it is the first to survive up to about 24
months. The other dynein homozygous mouse models were either embryonic lethal or the
mice died soon after birth. Therefore, only data from mouse embryos have been studied,
there is no data on the progression of disease in the adults. This means that with the
H304R/R homozygous dynein mouse model there is the opportunity to systematically
investigate disease pathways and obtain purified mutant protein that can be used in
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various cellular assays to better understand how dynein structure and function is altered
in a diseased mouse.

4.3.1.3 Nuclear morphology at the Neuromuscular Junction
Nuclei that are found localized specifically at the NMJ continue to be the subject of much
interests because of how they contribute to the maintenance of the NMJ and the
transmission of nerve impulses. An understanding of how they could be affected in
disease conditions will be important in finding out more about how the entire
neuromuscular synapse is altered. We conducted an analysis of nuclear morphology in
wild-type and mutant mice. We observed severe neuromuscular deficits in 12-month-old
male mice, and so we started by looking at these cohorts. Differences exist in the
morphology of nuclei in the different genotypes with the wild-type mice having more
rounded nuclei and less elongated nuclei. There is a shift from a mixture of both rounded
and oval morphs in heterozygous mice to a predominantly elongated oval nuclei in
homozygous tissue. This observation could be due to a number of possibilities; the
presence of more glial cells in the wild type mice compared to the other 2 mutants
(heterozygotes and homozygotes). It is also possible that the defects in dynein function
affect the placement of glial cell nuclei during development resulting in a reduction in the
number of myonuclei. Researchers in an ALS study examined the link between
denervation and expression of the glial marker, S100 (Carasco et al,2016). They found
no expression of S100 under conditions of denervation, mice with an ALS mutation
(SOD1-G93A) are more susceptible to losing the expression of S100 compared to normal
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mice. This scenario is entirely possible in our study, since we have shown that
homozygous mice have more denervated NMJs. Further studies would help us establish
whether a correlation exists between the denervation of the NMJ and reduced expression
of S100 in a dynein disease model. It will also be important to ascertain whether the
differences in nuclear distribution and morphology between wild-type and H304R
mutants (both heterozygous and homozygous) occur at other time points too.
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CHAPTER 5:CONCLUSION
5.1

The generation of a novel mouse model to study dynein function

Dynein function has been widely studied for several years in various systems and that has
contributed immensely to our understanding of how the motor protein functions within
cells. The ability to genetically manipulate portions of the dynein-dynactin complex have
been invaluable in deciphering how its functions are needed in cells. The introduction of
the three dynein heavy chain mouse models, loa, cra, swl drew the attention of the entire
field to the critical role dynein plays in neuronal cells. Various studies into these mouse
models brought to the fore how dynein-mediated retrograde transport may be essential for
the survival of neuronal cells (Hafezparast et al, 2003). There is therefore a two-fold
limitation with these mouse models. First, the exact mechanistic pathway through which
the mutation in the dynein heavy chain gene results in disease is not clear. The other
limitation is that the loa, cra, swl mutations are not related to a disease in humans, there
is therefore a bit of a difficulty in relating the findings to humans. We successfully
generated a knock-in mouse model of CMT2O disease bearing a point mutation (H304R)
in the dynein heavy chain which corresponds to H306R in humans. Our characterization
of this mutant mouse revealed a predominant motor phenotype as seen in human CMT2
disease. This was confirmed through our assays by weakness in the muscle and motor
coordination defects. The phenotypic study conducted in loa, cra and swl mice was not
done in a longitudinal manner and so did not cover all the timepoints in the H304R study.
However, phenotypic defects in H304R heterozygous mice are milder in comparison to
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loa, cra, swl mice. The H304R/R homozygous mouse model on the other hand, appears
to have more robust behavioral characteristics compared to loa,cra, swl heterozygotes.
The H304R mouse model is therefore a novel and distinct system that can be used to
study dynein function. The fact that it is linked to a disease in humans addresses the issue
of relevance in the search for therapeutics and makes it suitable for translational research.

5.2

Connecting the dots between dynein mutations and neurological disorders

The ultimate goal of our study is to understand dynein function better, and in the specific
case of our H304R mouse model, we hope to achieve this aim by following the onset and
progression of CMT2O disease, caused by a mutation in the dynein heavy chain gene.
We have shown that the neuromuscular junction is a pathological target in CMT2O
disease (Sabblah et al, 2018). The abnormalities in the NMJ are obvious in both
heterozygous and homozygous models, with the deformities worsening in the
homozygotes. There is still more work required to arrive at a mechanism for CMT
disease in our H304R mouse model. A legitimate question that arises is how does dynein
function affect NMJ architecture? It is known that dynein transport of essential cargoes
in axons towards the nucleus is important in many neuronal processes (Levy and
Holzbaur, 2006). We can therefore hypothesize that NMJ defects in H304R mouse
models are partly due to dynein dysfunction in the motor neurons that innervate the axon.
There is evidence of that in our study where we saw reduced innervation and a
concomitant increase in NMJ dysmorphology at later stages in heterozygous mice.
Dynein activity in the muscle could also be a contributory factor. It was discovered that
disrupting dynein function alters the components of the neuromuscular synapse in
primary myoblasts from mice (Vilmont et al, 2016). Our initial analysis of subsynaptic
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nuclei at the NMJ suggests a difference in the distribution and morphology of nuclei in
mutants compared to wild-type. This could be another pathway that disrupts the NMJ
organization in H304R mutant mice since dynein is an essential player in myonuclear
positioning (Folker et al, 2014).

We cannot rule out the possibility of a structural defect in the dynein protein itself or a
change in interaction with its binding partners. The dynein motor protein is a massive 1.6
MDa complex made up of four kinds of subunits that need to be present in the right
stoichiometric proportions to be assembled into a functional unit. In addition to that, the
dynein complex interacts with other key adaptors and regulators like dynactin, BicD, Lis1
that are required for complete function in cells. A mutation in any of the dynein subunits
could possibly affect how the subunits interact or how other accessory proteins interact
with dynein and ultimately alter dynein function to cause disease. Interestingly, a study
involving 14 DYNC1H1 heavy chain mutations, did not find any change in the
association of dynein with dynactin-BICDN complexes in majority of the human
mutations, including the H306R mutation (Hoang et al, 2017). With that being said, it
will be interesting to know what the dynein subunit levels are in the H304R homozygous
mutant as well, and what kind of outcomes will be obtained from single-molecule assays
using only a homogenous population of mutant protein.
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Figure 30 Severity of phenotypes continuum
Comparison of the severity of mouse DHC mutations with the CMT2O DHC phenotypes
observed in human patients. Heterozygous mouse H304R/+ phenotypes are similar to
those of H306R/+ CMT2O patients. Heterozygous mouse loa/+, cra/+, swl/+ phenotypes
are more severe than those of H304R/+ mice. Homozygous H304R/R phenotypes are
more severe than loa/+, cra/+, swl/+ phenotypes. Homozygous loa/loa, cra/cra, swl/swl
phenotypes are the most severe resulting in death.
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5.3

So how does the H304R mutation cause disease?

Studies in N. crassa involving the expression of various dynein heavy chain mutations
resulted in 5 different classes of phenotypes based on the localization of cytoplasmic
dynein in the hyphae (Sivagurunathan et al, 2012). What this study taught us is that
phenotypes generated from dynein heavy chain mutations are heterogeneous. Pleiotropic
manifestations are observed in the different human mutations as well. The majority of the
dynein heavy chain (DHC) mutations are described as SMA-LED (spinal muscular
atrophy with a lower extremity predominance based on their features in patients. The
SMA-LED phenotype is mainly characterized by lower muscle atrophy and weakness.
There were other neurological defects in humans with mutations in the dynein heavy
chain gene. Some patients with the H306R mutation which causes CMT2O disease had
pes cavus and an abnormal gait. Less common manifestations of the disease include
impaired speech and learning difficulties (Weedon et al, 2011). Intellectual disorders
have also been reported in other dynein heavy chain mutations (Strickland et al, 2015,
Scoto et al 2015). Malformations of cortical defects were observed in some dynein heavy
chain mutations as well (Poirier et al,2013). Even though there are over 20 dynein heavy
chain mutations discovered in humans, there isn’t a lot known about the prevalence for
any one individual mutation or all of the DHC mutations. The first publication about
dynein heavy chain mutations in humans came out about 7 years ago, which makes it
quite a short period of time to have volumes of data to compute prevalence rates. Perhaps
epidemiological data will become available after a while when more cases are reported.
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The point to note is that the heterogeneity of the disease manifestations could be strongly
linked to the mechanism of the disease. In simple terms, multiple manifestations could be
due to multiple disease pathways. Another significant observation regarding the
phenotypes of DHC mutations is the variation in severity. Differences in the extent of the
disease manifestation could occur within a cohort, varying from individual to individual,
as previously reported in human patients (Weedon et al, 2011, Scoto et al, 2015). We
however wanted to capture any differences that might exist among different DHC
mutations. By comparing our H304R mouse model with other dynein mouse models
namely loa, cra and swl, we noticed differences in how the mice are affected by
mutations in the DHC gene (Figure 30). We are unable to determine which of the other
DHC human mutations would correspond to those of the mouse DHC genes since there
are no mouse models for those other human mutations.

Beyond the motor phenotype observed in the behavioral assays, we were interested in
uncovering dynein related functions that could be contributors to CMT disease in the
H304R mutant mice. Neuromuscular junction defects have already been reported in
dynein and CMT2 mouse models (d'Ydewalle et al, 2011, Sleigh et al, 2014, Spaulding et
al, 2016, Courchesne et al, 2011). NMJ analysis in the dynein H304R mutant mice also
unveiled dysmorphology and reduced complexity which were even worse in the
homozygous mice.

To probe dynein dysfunction even further, it is important to consider the tripartite
components of the neuromuscular apparatus, namely the motor nerves, the muscle fiber
and the terminal Schwann cells. Dynein function has been studied in the motor and
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neuron and in muscles but not much is known about dynein function in Schwann cells
especially the terminal Schwann cells that cap the neuromuscular junction. We observed
innervation defects in H304R mice, pointing to possible defects in dynein-mediated
transport in the axons. The dynein complex transports cargo from the synaptic end of the
axon to the soma, some of these include, molecules marked for degradation, recycling
endosomes and ribonucleoproteins. Dynein dysfunction could lead to a reduction in
transport efficiency and may even impact kinesin-mediated anterograde transport. This
could be a very important factor in the development of disease because some cargo are
transported in both anterograde and retrograde directions (Brady et al, 1990, Hendricks et
al, 2010).

This could partially explain why the perturbation of dynein function via a point mutation
in the heavy chain gene for instance, will result in defects in neuromuscular abnormalities
in an organism. Knock out studies done in mice have shown that without dynein, mice
die art the embryonic stage (Harada et al,1998). As such we expect that mice that survive
with a dynein mutation would not have a complete loss of dynein function. Additionally,
the fact that H304R mutant mice are ambulatory means there may not be a grave
malfunction such as the inability to transport cargo but rather an alteration of dynein
function leading to a delay in the delivery of some kind of cargo sounds more likely. The
slight change in dynein function is probably the reason why CMT2O patients have a
slowly progressing motor and sensory neuropathy. In these patients also, the onset is
variable and so is the phenotype of the disease. Motor neurons may be vulnerable to
dynein mutations by their length, which represents a large distance over which cargo has
to be transported. Most of the proteins required by neurons are synthesized in the soma
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and must therefore be delivered to the various compartments where they are needed. This
makes axonal transport indispensable to neuronal survival. The defective axonal transport
model is a likely mechanism in the H304R dynein heavy chain gene mutation that causes
CMT2O disease.

Work done in cultured muscle cells showed a direct involvement of dynein in the
organization of the post-synaptic apparatus. The inhibition of dynein function led to
aberrations in the trafficking of the muscle specific kinase (MuSK), which helps cluster
the receptors and maintain the structural cohesion of post-synaptic components (Vilmont
et al, 2016). The possibility of MuSK transport being a key driver of NMJ
dysmorphology in H304R mutant mice would require further studies using cells from the
muscles of mice. Such an investigation at the cellular level will enable us to assess other
dynein functions like the maintenance of Golgi and microtubule integrity. Dynein
functions in muscle development although myosin is the molecular motor required for
contraction in the muscle. Dynein is involved in the movement and placement of
myonuclei, which is very critical in muscle function. As muscle cells are syncytial, the
positioning of nuclei occurs at defined intervals to create sectors of transcriptional control
for each nucleus (Bruusgard et al, 2003). Live cell experiments in the fruit fly show
dynein is needed to properly position myonuclei (Folker et al, 2014). A similar
mechanism may be needed to cluster nuclei at the synaptic region that are in close
proximity to the AChR in the muscle. Preliminary results from our lab suggest a
difference in nuclear distribution in the synaptic region (Figure 29). The synaptic nuclei
also contribute to the AChR pool that is clustered to ensure efficient communication from
the nerves (Ferraro et al, 2012). This means that changes in the organization of sub118

synaptic nuclei arising from the H304R mutation could be a factor in the reduced
complexity observed in mutant NMJs.
There isn’t much information about dynein function in glial cells. Dynein is known to
play a role in myelination in zebrafish via its involvement in the expression of some vital
genes (Yang et al, 2015). Work done in oligodendrocytes of zebra fish specifically
identified myelin basic protein (MBP) as a cargo transported by the dynein/dynactin
complex, and disrupting this complex reduces the expression of MBP, which is required
to maintain myelin stability (Herbert et al, 2017). Without much evidence specifically
linking cytoplasmic dynein function to terminal Schwann cells, the scenario where
dynein influences the expression of vital genes in the terminal Schwann cells still remains
a possibility that has to be adequately tested. The ubiquity of dynein and its multifarious
roles in living organisms reflects in the mechanisms of diseases that result from DHC
mutations. In H304R mutant mice it is likely that a combination of altered dynein
transport defects in the motor neuron, defective trafficking of one or more synaptic
components and dysfunction in glial cells at the neuromuscular junction contribute to the
predominant motor defects observed in mutant mice.
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ABSTRACT
Charcot Marie Tooth disease (CMT) represents the most common inheritable peripheral
group of motor and sensory disorders; affecting 1 in 2500 people worldwide. Individuals
with CMT experience slow progressing weakness of the muscle, atrophy, mild loss of
motor coordination and in some cases loss of sensory function in the hands and feet
which could ultimately affect mobility. Dynein is an essential molecular motor that
functions to transport cargos in all cells. A point mutation in the dynein heavy chain was
discovered to cause CMT disease in humans, specifically CMT type 2O. We generated a
knock-in mouse model bearing the same mutation(H304R) in the dynein heavy chain to
study the disease. We utilized behavioral assays to determine whether our mutant mice
had a phenotype linked to CMT disease. The mutant mice had motor coordination defects
and reduced muscle strength compared to normal mice. To better understand the disease
pathway, we obtained homozygous mutants from a heterozygous cross, and the
homozygotes show even more severe deficits compared to heterozygotes. They also
developed an abnormal gait which separates them from heterozygous mice. In view of the
locomotor deficits observed in mutants, we examined the neuromuscular junction (NMJ)
for possible impairments. We identified defects in innervation at the later stages of the
study and abnormal NMJ architecture in the muscle as well. The dysmorphology of the
NMJ was again worse in the homozygous mutants with reduced complexity and
denervation at all the timepoints assessed. Our homozygous dynein mutants can live up to
two years and therefore make the design of longitudinal studies possible. Altogether, this
mouse model provides dynein researchers an opportunity to work towards establishing
the link between dynein mutations, dynein dysfunction and the onset and progression of
disease.
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